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The human cystathionine β-synthase (CBS) is a 5’ pyridoxal phosphate (PLP)
dependent protein that catalyzes the condensation reaction between serine and
homocysteine to yield cystathionine. This is the first step in the transsulfuration pathway
which connects the methionine cycle to cysteine production. Mutations in CBS are the
single most common cause of severe hereditary hyperhomocystenemia and over one
hundred pathogenic mutations have been described so far. These mutations represent
residues which are important for the structural and functional integrity of the enzyme.
The biochemical characterization of these mutants thus leads to further insights into
structure-function correlations in CBS.
CBS has a subunit mass of 63 kDa and is a modular protein with 551 amino acids.
The N-terminal half of the protein houses the two cofactors, PLP and heme and a CXXC
motif comprised of residues C272 P273, G274 and C275. This motif is also found in the
thioredoxin family of proteins where it is involved in thiol disulfide exchange reactions.
The heme, which is coordinated by the axial ligands H65 and C52, is about 20 Å away

from the CXXC motif as well as the PLP catalytic center. As such, heme does not
contribute directly to catalysis, but is believed to be a center for redox regulation in CBS.
The C-terminal half of the protein comprising residues 413 to 551 bear a tandem
repeat of “CBS domains,” which are secondary structural motifs found in diverse families
of proteins with no sequence similarities. In CBS, these domains are believed to be
involved in the binding of the allosteric activator S-adenosyl methionine (AdoMet).
Along with being involved in allosteric regulation, the C-terminal domain of CBS
imposes intrasteric regulation on the catalytic core. Thus deletion of the C-terminal
regulatory domain leads to the formation of a super-active enzyme, CBS-ΔC143 which
has a 4-fold higher kcat than the full-length protein. It is also known that a truncated form
of CBS is generated in cells exposed to proinflamatory agents such as TNFα. Although
this observation suggests that the C-terminal domain interacts with the N-terminal
catalytic core to effect this regulation, so far no experimental results were available which
would characterize the nature of this interaction. In other words no information was
available regarding the conformational changes associated with the allosteric and
intrasteric regulation in CBS.
In this study, we have mapped the regions of intrasteric and allosteric regulation in
CBS. We have employed hydrogen/deuterium (H/D) exchange, mass spectrometric
technique to locate conformational changes in the enzyme upon the binding of its
allosteric activator, AdoMet. We have also used this approach to detect the surface
involved in the interaction of the C-terminal domain with the catalytic core relevant to
intrasteric regulation. A change in the kinetics of H/D exchange was located in a single
peptide, extending from residues 511-531 upon AdoMet binding. CBS-D444N a patient

mutant exhibits a similar change in the above peptide in its native state and thus samples
a conformation which is acquired by the wild type upon AdoMet binding. Accordingly
this mutant is not responsive to any further activation by the allosteric activator. Peptides
356-370 and 371-385 in the N-terminal half of the protein exhibited a change in H/D
exchange kinetics when the full-length and its counter part in CBS-ΔC143, were
compared by H/D exchange studies, associating this region with intrasteric regulation.
We have also demonstrated that in addition to heme, the CXXC motif in CBS is a center
for redox regulation. Thiol alkylation followed by mass spectrometric analysis
demonstrated formation of an intramolecular disulfide bridge between C272 and C275,
and identified the presence of a sulfenic acid intermediate under air oxidized conditions
in CBS-ΔC143. The full length and the CBS-ΔC143 enzyme exhibited a 1.6 and 4.5 fold
enhancement in specific activity respectively upon reduction of their disulfides at the
CXXC center. A redox potential of -240 ± 4 mV was determined for the CXXC center
using MAL-PEG for titrating thiol content at various ratios of oxidized and reduced
dithiotreitol.
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Chapter1
Introduction

2

1.1 Toxicity of homocysteine
Homocysteine is a non protein sulfur containing amino acid formed during the
metabolism of an essential amino acid methionine. Carson and Neil independently
described the first error in methionine metabolism by demonstrating an excessive urinary
excretion of homocysteine in children who had a deficiency in CBS activity (5).
Following this, it was also reported that children with homocystinuria, an autosomal
recessive condition showed signs of cardioavascular disorders (35). This lead Dr. Kilmer
Mc Cully to suggest a correlation between high levels of homocysteine and
cardiovascular diseases (26, 35). Studies over the last twenty-five years have shown that
even, mild elevation of homocysteine in the plasma is an independent risk factor for
occlusive arterial disease, venous thrombis and vascular causes of mortality (26). More
than fifty percent of patients with stroke and/or other cardiovascular diseases have
homocysteine levels outside the normal range, which is around 10-15 µM for men and 610 µM for women. High levels of homocysteine, are also correlated with several other
diseases such as neural tube defects and Alzheimer’s diseases (20, 36).

1.2 Role of cystathionine β-synthase in metabolism
Cystathionine β-synthase [EC 4.2.1.22: CBS], is a heme protein and catalyzes the
pyridoxal 5’- phosphate (PLP)-dependent condensation of serine and homocysteine to
form cystathionine (63). CBS catalyzes the only reaction that irreversibly removes the
toxic metabolite, homocysteine, from the methionine cycle. This is followed by the
action of a second PLP dependent enzyme, cystathionine γ-lyase which catalyzes the
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hydrolysis of cystathionine to α-ketoglutarate and cysteine, a precursor of the major
cellular redox buffer, glutathione. Thus CBS catalyzes the first committed step in the
transulfuration pathway. Homocysteine, a non-protein sulfur containing amino acid
occupies a key biochemical intersection in the methionine cycle between S-adenosyl
methionine (AdoMet), the indispensable and ubiquitous methyl group donor in various
biological reactions. Homocysteine metabolism is thus regulated to strike a balance
between the methylation and transulfuration pathways and to maintain low levels of this
toxic metabolite (13).

1.3 Regulation and homocysteine metabolism
Homocysteine is an intermediate in methionine metabolism and is cleared via one of
two pathways: the remethylation pathway which regenerates methionine by transfer of a
methyl group to homocysteine, and the transsulfuration pathway that degrades
homocysteine into cysteine (Fig1.1). Remethylation of homocysteine to methionine is
catalyzed by one of two zinc enzymes, cobalamin–dependent methionine synthase (MS)
and betaine homocysteine methyl transferase. Another important enzyme in the
remethylation pathway is methylenetetrahydrofolate reductase (MTHFR) that generates
methyl tetrahydrofolate, the methyl group donor for the methionine synthase–catalyzed
reaction. Although both MS and betaine homocysteine methyl transferase, catalyze the
remethylation of homocysteine betaine homocysteine methyl transferase has limited
tissue distribution being present mainly in the liver and kidneys (19), whereas MS is
ubiquitous.
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AdoMet, a ubiquitous methyl donor in various metabolic reactions including RNA,
DNA, lipid and protein methylations and a precursor of polyamines, is synthesized by
adenosylation of methionine catalyzed by methionine adenosyltransferase. AdoMet is
demethylated by a variety of methyl transferases to give S-adenosyl homocysteine, which
in turn is hydrolyzed to give adenosine and homocysteine catalyzed by S-adenosyl
homocysteine hydrolase.
Homocysteine is at a branch point in methionine metabolism. In liver cells,
approximately half of the total homocysteine formed is remethylated back to methionine
and half is committed to the transsulfuration pathway (16) for the synthesis of cysteine.
The transulfuration pathway also provides a route for the disposal of excess sulfur via
cysteine catabolism. The flux of homocysteine through the complex pathways is tightly
regulated. One regulatory switch between methionine cycle and transulfuration pathway
is AdoMet (14). At high concentrations of AdoMet, remethylation of homocsyteine to
methionine is inhibited (15, 60). High concentrations of AdoMet signal methionine
sufficiency and represses remethylation by inhibiting MTHFR, the source of methyl
tetrahydrofolate, the methyl donor in the reaction catalyzed by methionine synthase.
Under the same conditions, CBS is activated by AdoMet which increases flux of
homocysteine through the transulfuration pathway. It is estimated that ~ 50% of cysteine
in the intracellular glutathione pool is derived from homocysteine via the transulfuration
pathway in liver cells (43, 61). Thus, regulation at the level of CBS directly controls the
removal of homocysteine from the methionine cycle, thereby influencing glutathionebased redox homeostasis.
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Figure1.1. An overview of homocysteine metabolism.

Enzymes involved in methionine metabolism cycle are also regulated by the redox status
of the cell. AdoMet synthesis from methionine has been shown to be responsive to
oxidative stress. The two isoforms of methionine adenosyltransferase that catalyze
AdoMet synthesis are down-regulated under oxidative stress conditions marked by a low
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GSH/GSSG ratio. This inhibition is reversed with GSH (48, 50). MS and CBS, the two
enzymes which use homocysteine as a substrate, both contain redox active cofactors and
are reciprocally sensitive to oxidative stress providing an additional level of regulation
for switching between the methionine cycle and the transulfuration pathway (7, 56).
Under oxidative conditions MS is inhibited due to the oxidation of its cofactor
cob(I)calamine to cob(II)calamine and by the possible oxidative modification of the
cysteine ligands to the active site zinc (7). In CBS however, redox regulation is
potentially complicated and occurs at two centers in the enzyme. Studies in our
laboratory have shown that the reduction of the heme in CBS leads to an approximately
2-fold diminution in its specific activity (56). On the other hand, reduction of the
disulfide bridge in the CXXC motif enhances its activity (Sen S, Banerjee R, unpublished
data). The opposing redox regulation by the heme and the CXXC motif of CBS activity
suggests that it is most active when the CXXC motif is reduced and the heme is oxidized
and least active when both redox centers are either fully reduced or fully oxidized.
Addition of H2O2 or tertiarybutyl hydroperoxide to cultured human liver cells induces
oxidative stress leading to a 2-3 fold increase in the flux of homocysteine through the
transulfuration pathway (43). Another mechanism for oxidative activation of CBS is the
targeted endoproteolysis to generate the truncated dimer. This is observed under some
conditions, e.g. when the cytokines TNFα is added to cultured human cells (65). Under
these conditions AdoMet activation is lost consistent with the cleavage of the C-terminal
regulatory domain. In vitro truncated CBS has four-fold higher kcat than full length CBS
and is not regulated by the allosteric activator AdoMet (57). TNFα induced targeted
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proteolysis of CBS is inhibited by scavengers of superoxide production or by the
overexpression of manganese superoxide dismutase (65).

1.4 Impairments in homocysteine metabolism and disease
High levels of homocysteine have been correlated with various diseases affecting the
cardiovascular, neural, ocular and skeletal organ systems. Mutations in CBS or in MS,
the two most prevalent homocysteine-utilizing enzymes, or perturbations in their
regulatory systems, lead to elevated levels of plasma homocysteine. Further mutations in
homocysteine utilizing enzymes, or perturbations in their regulatory systems are the most
common cause of elevated levels of plasma homocysteine. Further mutations in
methyltetrahydrofolate reductase, which indirectly affects homocysteine clearance is also
associated with homocystinurea as are mutations in MS reductase an enzyme required for
regulation of active MS (58),(59). Elevated levels of homocysteine can also result from a
diet poor in vitamins as many enzymes involved in this pathway utilizes vitamins such as
folic acid, cobalamin (B12) and PLP (B6) as their cofactors. High levels of homocysteine
are accompanied by high levels of AdoHcy, which is a potent inhibitor of AdoMet–
dependent methylation reactions (10), (21). CBS deficiency impairs flux through the
transulfuration pathway and leads to defects in sulfur metabolism including glutathione
biosynthesis. In healthy individuals, plasma homocysteine levels range from 10-15 µM.
Concentrations ranging from 15-100µM and > 100 µM are classified as moderate
hyperhomocysteinemia and severe hyperhomocysteinemia respectively (38), (37).
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Severe hyperhomocysteinemia, an inherited autosomal metabolic disorder, is
characterized biochemically by high levels of homocysteine in the plasma and in the
urine

(39).

CBS

deficiency

is

the

most

common

cause

of

hereditary

hyperhomocysteinemia (45). Clinically, this disease is characterized by thrombosis,
mental retardation, premature artherosclerosis, connective tissue disorders including
osteoporosis, lens dislocation and skeletal abnormalities resembling Marfan syndrome
with long thin extremities, decreased upper/lower segment ratio and arachnodactyly (44).
Studies showed that about 30% of homocystinuric patients experience stroke or heart
attack by the age of 20 (45).
Hyperhomocysteinemia due to CBS deficiency is distinct from other defects leading
to homocystinurea. Connective tissue disorders are also associated with CBS deficiency
(9).

1.5 CBS gene map
The CBS gene maps to the subtelomeric region of the human chromosome 21
(21q22.3) (37, 38) and contains 23 exons, spanning a region of 30 Kb. The CBS
polypeptide has 551 amino acids and is encoded by exons 1 through 14 and exons 16.
Exon 15 is alternatively spliced and is detected only rarely in mature mRNA molecules.
The 14 amino acids encoded by this exon have not been detected in the CBS polypeptide
from various mammalian tissues (33), (31). The 5’ UTR of human CBS is encoded by
one of five alternatively used exons, -1a b, c, d, e, and exon o present in the CBS gene.
The 3’UTR is encoded by exons 16 and 17 (33). A polymorphism found in 5% of normal
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Caucasian alleles has been described in which exon 8 has a 68 bp fragment insertion,
8444ins68 that is spliced out from the mature mRNA (52).

1.6 Structural and functional properties of the human CBS
Human cystathionine β-synthase (CBS), a key enzyme in sulfur metabolism,
catalyzes the condensation reaction of homocysteine and serine to yield cystathionine
(Scheme 1). This is the first of two PLP-dependent steps in the transulfuration pathway
which converts methionine to cysteine.

Scheme 1. Schematic representation of the reaction catalyzed by CBS.

The cysteine formed is used for multiple purposes including the synthesis of glutathione
which is present at high concentrations and is involved in maintaining cellular redox
balance. Under conditions of oxidative stress, the flux of sulfur through the
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transulfuration pathway increases resulting in a concomitant rise in glutathione synthesis
(41).
CBS is a unique PLP- dependent enzyme in that it is also heme dependent. The
enzyme exists as a tetramer and a mixture of higher oligomers ranging from a dimer to a
16- mar (17). The subunit molecular weight is ~63 kDa. Each subunit binds one heme
and one PLP. The V–type allosteric activator AdoMet binds stoichiometrically to each
subunit and increases the activity of the enzyme by 2- to 3- fold (34).
CBS is a modular protein, the N-terminal domain of which houses the heme and PLP
cofactors along with a -CPGC- motif commonly found in the active sites of thioredoxin
family of proteins involved in thiol disulfide exchange reactions (22). The C-terminal
domain comprises the regulatory third of the protein and houses a tandem repeat of “CBS
domains”, a β-α-β-β-α secondary structure motif found in a variety of unrelated proteins
in all three kingdoms of life (2). AdoMet, the allosteric activator is believed to bind to the
CBS domains (51).
Crystal structure of the truncated dimer of CBS
The crystal structure of a truncated dimeric form of human CBS, lacking the
regulatory domain (413-551) has been solved (Fig 1.2) (24), (55). The fold of the
truncated human CBS enzyme belongs to the β-family of vitamin B6 enzymes (1) and
resembles the fold found in O-acetyl-serine sulfhydrylase from Salmonella typhimurium
(4).
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PLP

Heme

CXXC

Fig 1.2. Ribbon representation of the crystal structure of the truncated dimer of CBS.

Three other PLP enzymes whose structures are known share the same fold type:
tryptophan synthase (23), threonine demainase (18) and aminocyclopropane deaminase
(64). A least square superposition of the Cα-positions of the structurally conserved parts
between CBS and O-acetyl-serine sulfhydrylase yields a root mean square deviation of
only 1.32 Å with the differences between the structures being mainly located in the loop
regions.
The CBS monomer is composed of 11 α helices, seven short 310 helices and two βsheets consisting of four and six strands in the N-terminal and C-terminal domains
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respectively. The heme binding domain is largely unstructured with the exception of a
short 310 α-helix. The dimer interface is highly hydrophobic in character. The central part
of the dimer interface is formed by residues F 111 and F112 close to the 2-fold dimer
axis. F 112 of one monomer thus interacts with F112 of the other. Although hydrophobic
interactions dominate at the interface, polar interactions also contribute to dimer
formation. PLP is deeply buried in a cleft between the N-terminal third and the Cterminal regulatory domain. The active site is accessible only by a narrow channel. The
cofactor is linked to the ε-amino group of K119 via a Schiff base linkage forming the
internal aldimine. The nitrogen of the pyridine ring forms a hydrogen bond to the Oγ of
Ser349 similar to the other enzymes of β-family of PLP enzymes. A second hydrogen
bond is formed between the 3’ hydroxyl group of PLP and the Nδ2 of Asn149. This
residue is coplanar with the pyridine ring and thus allows the expected ring tilt upon
transaldimination. The phosphate binding groups Gly256, T257, G258, G259 and T260
form extended hydrogen bonds with the phosphate moiety of the PLP anchoring the
cofactor to the protein matrix. Residues Y223 and G307 are probably key residues for
substrate specificity, as they are spatially adjacent to the inferred substrate binding site.
The heme in CBS
Each dimer contains two hemes located at distal ends of the dimers with the
orientation of their planes normal to the plane of the protein. The heme spectrum of CBS
analyzed by the pyridine hemechrome method is typical of iron protophorphyrin IX (61).
Ferric CBS, as isolated, exhibits a Soret absorption maximum at 428 nm and a broad αβband centered at ~550 nm, which is typical of low-spin 6- coordinate heme. The heme is
bound in a hydrophobic pocket formed by residues 50-67, α-helices 6 and 8 and a loop
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preceding β-strand 10. The sulfhydryl group of C52 and the Nε2 atom of H65 coordinate
the heme axially. The sulfur atom of C52 is believed to be deprotonated (12) and engages
in additional interactions with the side chain of R266 and the main chain nitrogen of
W54. The carboxylate groups of heme are involved in ionic interactions with R51 and
R224 and are partially solvent exposed unlike in cytochrome c peroxidase and
cytochrome P450 iron, where the heme is buried in an internal cavity in the protein (40).
Since the iron ion is ligated from both sides by protein residues and that the heme is
located almost ~20 Å away from the active site, it rules out a catalytic role for heme.
Carbon monoxide binds to the ferrous heme displacing the thiolate ligand (57). The
enzyme retains 25% of activity under such conditions (3). Reduction of the heme from +3
to +2 oxidation state is correlated with a decrease in enzyme activity by ~1.5 fold under
in vitro assay conditions. The Soret peak at 428 undergoes a red-shift to 450 nm under
reduction of the heme with titanium citrate or dithionite (56), (46) with a concomitant
sharpening of the αβ- bands at 540 and 571 respectively. A midpoint potential of -350
mV has been measured for the heme in full length CBS and -287 mV in the truncated
variant (Madzelan P, Banerjee R, unpublished results). Ferric CBS shows a bell shaped
pH dependence on enzyme activity with pKa1 and pKa2 values of 7.9 ± 0.2 and 8.8 ± 0.2
respectively (56). The electronic absorption spectrum of ferric CBS is independent of pH
in the range 6-9 (8), indicating that a change in the heme environment is not related to the
kinetic pKas. The properties of the ferrous heme however are affected by both pH and
temperature (8).
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The CXXC motif in CBS
Residues 272 through 275 comprise the CXXC motif in CBS. In the crystal structure,
the loop between α-helix 8 and β-strand 9 harbors this motif and is similar to that seen in
active sites of disulfide oxidoreductases. The consensus sequence in this motif in
oxidoreductases contains two cysteines that are linked by two residues one of which is
proline (Table 1).
C272
Human
Monkey
Rat
Mouse
Frog

C275

-KCPGCR-KCPGCR-KCPGCK-KCPGCK-KCPNCK-

Table 1. Sequence alignment of the CXXC motif.

The CXXC motif in oxidoreductases is involved in various redox reactions in the cell,
because they can be reversibly oxidized and reduced by switching between a disulfide
and dithiol form during a catalytic process. In CBS, this motif consists of CPGC and
forms a β turn. In the two crystal structures of truncated CBS (55), the CXXC motif is
seen in both the disulfide bridge and the dithiol forms. The structure of glutaredoxin from
Escherichia coli can be superimposed onto CBS. In this superimposition, α-helix 1 of
glutaredoxin merges onto α-helix 7 of CBS, and α-helix 3 onto α-helix 8 of CBS albeit
in opposite directions (55). The four strands of the central β-sheet of glutaredoxin fit onto
strands 3, 8, 9 and 11 of the C-terminal domain of CBS. In CBS, the CXXC motif is
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found at a location corresponding to the N-terminal end of α-helix 3 of glutaredoxin,
while in glutaredoxin it is located at the N-terminal end of α-helix 1 (55). Thus, in
addition to heme, the CXXC motif is another redox-active center in CBS.

1.7 Intrasteric and Allosteric Regulation in CBS
Purification of the wild-type enzyme from mammalian liver has resulted in the
isolation of mixtures of the full-length as well as truncated but active dimeric forms of
the enzyme (30). Limited proteolysis also yields a 45 kDa subunit and is accompanied by
a change in the oligomeric state representing a dimer. This form of the enzyme
represented the catalytic core and extends from amino acids 31, 37, or 40 through 413
and exhibits a kcat which is 4-fold more than the full-length enzyme. The N-terminus of
this polypeptide is heterogeneous due to multiple susceptible proteolytic sites at lysines
30, 36 and 39. Alternatively the catalytic-core can be generated by introduction of an opal
mutation at position 409 in the open reading frame and the resulting protein extends from
residues 1 to 408 (CBS-ΔC143) (54). The activity of this variant, was higher than that of
the full-length (27). A truncated variant is also formed upon TNFα exposure in liver cells
(65). The latter was also shown to be more active than the full-length enzyme and lacked
allosteric regulation (57). Together these observations showed that the C-terminal
regulatory domain imposes intrasteric regulation on the catalytic core. AdoMet which is
believed to bind to the C-terminal domain of the full-length enzyme relieves this
intrasteric inhibition. Binding of AdoMet increases the Kcat of the full length enzyme ~2
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to ~3 fold, while truncation beyond the catalytic core increases kcat ~4 fold compared to
the basal activity associated with the full-length enzyme (57).
A patient mutation D444N located in the C-terminal domain, is highly active but is
insensitive to allosteric regulation at physiological concentrations of AdoMet (11).
Another interesting patient mutation P78R/K102N in the N-terminal catalytic core of the
protein has recently been shown to be unresponsive to AdoMet (53). These observations
suggest that there exists a significant amount of interaction between the catalytic core and
the regulatory C-terminal domain. When this inter domain interaction is compromised as
in the above mutants they are rendered unresponsive to AdoMet. In addition to allosteric
regulation, binding of AdoMet to CBS also modulates the stability of the protein. The
half life of CBS in liver cells increases from 18 to 49 h in the presence of AdoMet (49).

1.8 Mutations in CBS
Mutations

in

CBS

are

the

most

common

cause

of

severe

hereditary

hyperhomocysteinemia (29). The vast majority of the mutations are missense with the
remainder being nonsense, deletion and insertion mutations (32),(42). Characterization of
patient mutations could lead to a better understanding of structural-functional correlations
in CBS. Over 130 pathogenic mutations have been described that are spread over the
coding and intronic sequences of the gene. The biochemical penalties associated with
some of the pathogenic mutants have been addressed but the majority remains
uncharacterized due to lack of a full-length crystal structure of the protein along with
difficulties associated with the purification of many of the mutants which tend to form
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aggregates (6), (25), (47). The two most common mutations in CBS are I278T and
G307S found in an Italyan population (28). CBS mutants may or may not respond to
PLP. Mutations in CBS are distributed along the whole length of the protein affecting
various structural properties depending on their localization. Some such P78R, R379Q
and E176K missense mutations localize to the dimer interface. Others are predicted to be
at the interface between the regulatory domain and the catalytic core (62). The S466L and
D444N mutations map on the CBS1 domain on the regulatory domain and the mutant
proteins do not respond to the allosteric activator AdoMet as the “CBS domains” are said
to be involved in nucleotide binding (62). A GST fusion of the isolated CBS domain pair
(residues 416-551) from CBS was shown to bind AdoMet with a Kd of 34 µM while the
D444N mutant increased the Kd by 15-fold to 510 µM (51).
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Chapter 2
Mapping Peptides Correlated with Transmission of Intrasteric Inhibition and
Allosteric Activation in Human Cystathionine β-Synthase
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2.1 ABSTRACT
Cystathionine β-synthase plays a key role in the intracellular disposal of
homocysteine and is the single most common locus of mutations associated with
homocystinuria. Elevated levels of homocysteine are correlated with heart disease,
Alzheimer’s and Parkinson’s diseases, and neural tube defects. Cystathionine β-synthase
is modular and subjected to complex regulation, but insights into the structural basis of
this regulation are lacking. We have employed hydrogen exchange mass spectrometry to
map peptides whose motions are correlated with transmission of intrasteric inhibition and
allosteric activation. The mass spectrometric data provide an excellent correlation
between kinetically and conformationally distinguishable states of the enzyme. We also
demonstrate that a pathogenic regulatory domain mutant, D444N, is conformationally
locked in one of two states sampled by the wild type enzyme. Our hydrogen exchange
data identify surfaces that are potentially involved in the juxtaposition of the regulatory
and catalytic domains and form the basis of a docked structural model for the full-length
enzyme.

2.2 Introduction
Equilibration between different conformational states often poses problems for
crystallization of modular proteins, thus limiting access to structural information.
Hydrogen exchange mass spectrometry is a powerful approach that can partially
circumvent this limitation. Thus, motions that are correlated with interconversion
between conformational states or with transduction of signals from sites distal to active
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sites can be localized (1, 2). Human cystathionine β-synthase is an example of a modular
protein that catalyzes the condensation of homocysteine and serine to give cystathionine.
This represents the first step in the transsulfuration pathway that connects the methionine
cycle to cysteine production and also provides an avenue for disposal of sulfur under
conditions of excess (3, 4). The structure of a truncated catalytic core (5, 6) but not of the
full-length protein is available, limiting structural insights into the dynamics that underlie
exertion of the complex regulation associated with this enzyme. Cystathionine β-synthase
is unique in being a PLP-dependent enzyme that also contains a heme b cofactor of
unknown function (7). In this enzyme, a central catalytic core houses the active site and is
interposed between an N-terminal heme domain and a C-terminal regulatory domain
(Figure 1) (3, 4). The regulatory domain per se exerts intrasteric control over the catalytic
module and its deletion results in an active form of the enzyme that displays a 4-fold
higher kcat but is unresponsive to the allosteric effector, S-adenosylmethionine (AdoMet)
(8, 9).The regulatory domain is also important in the oligomeric architecture of the
protein, and its deletion converts the native tetrameric (α4) enzyme to a dimeric (α2)
form. This transformation from the full-length to the truncated form lacking the
regulatory domain is observed in cells treated with the cytokine, TNFR, or in mice
challenged with the proinflammatory agent, lipopolysaccharide (10). A more modest
activation of the enzyme is observed with AdoMet, a V-type allosteric effector, which
enhances kcat ~ 2-fold (8) and is presumed to bind to the regulatory domain (11).
Mutations in cystathionine β-synthase are the single most common cause of
homocystinuria and over 100 disease-associated mutations have been identified in
patients (12). A subset of these pathogenic mutations maps to the regulatory domain
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appears to impose a conformational lock on the protein and is unresponsive to AdoMet
(13, 14). While the structure of the N-terminal catalytic core of cystathionine β-synthase
has been determined (5, 6), no structural information is available for the regulatory
domain, where the allosteric activator is presumed to bind (11). In this study, we have
employed hydrogen exchange mass spectrometry (MS) to identify peptides that respond

Figure 1. Modular organization and kinetic forms of human cystathionine β-synthase.
A. The domains in human cystathionine β-synthase include an N-terminal heme domain,
a central catalytic core and a C-terminal regulatory domain containing a tandem repeat of
two CBS domains. B. Kinetically distinguishable states of human cystathionine βsynthase. A, P, and H denote AdoMet, PLP, and heme, respectively.
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to the presence of AdoMet and those that respond to deletion of the regulatory domain, to
locate regions associated with intrasteric inhibition and allosteric activation, respectively.

2.3 Experimental Section
Materials. Deuterium oxide (100.00 atom % D) was purchased from Sigma. Pepsin (from
porcine stomach mucosa), and protease inhibitors were purchased from Sigma,porcine
trypsin was from Promega and thrombin (bovine) was purchased from GenTrac Inc.
Middleton, WI.
Enzyme Purification. Wild-type enzyme, the C-terminal truncated form (designated
ΔC143), and the D444N mutant were expressed and purified as previously described (8,
14, 15).
Limited Proteolysis of Cystathionine β-Synthase. Cystathionine β-synthase was subjected
to limited proteolysis as described in the Figure 2 caption and quenched at the desired
times with Nα-p-tosyl-L lysine chloromethyl ketone (Sigma).
Hydrogen-Deuterium Exchange. The feasibility of the H/D exchange MS method was
initially assessed for cystathionine β-synthase by determining the sequence coverage and
the spectral quality of its peptides. For this, cystathionine β-synthase (10 μg) in 100 mM
ammonium phosphate buffer, pH 2.2, was centrifuged to remove any insoluble matter
and digested with pepsin (1:1 w/w) for 5 min on ice. The peptic fragments were separated
by HPLC and identified by tandem ESI-MS/MS as described below. Approximately 76%
sequence coverage was obtained (Table 1 and Figure 2). One of the major peptides that
was not observed in this analysis extends from residues 252-287 and resides in a protease
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resistant core of the protein (16). Additionally, the peptides in the N-terminal heme
domain were not detected, which could have resulted from a paucity of pepsin cleavage
sites in this region. The mutant enzymes, ΔC143 and D444N (10 μg and 20 μg
respectively) in 10 mM phosphate buffer, pH 6.8, were diluted 20-fold in the exchange
buffer prepared in D2O (10 mM phosphate buffer, pD 6.8). For samples containing
cystathionine β-synthase complexed with AdoMet, the enzyme was preincubated with 1
mM AdoMet at room temperature for 2 h. For H/D exchange studies, samples were
incubated at room temperature for 5 to 60 s (to determine the effect of AdoMet) or
between 5 s and 21 h (to monitor the kinetics of hydrogen exchange in full-length
enzyme and the truncated variant, ΔC143) and quenched by a 2-fold dilution with 100
mM ammonium phosphate buffer, pH 2.2. The quenched samples were immediately
frozen in liquid nitrogen and stored at -80 °C until further use. Following thawing, the
samples were digested with pepsin as described above. To correct for loss of deuterium
incurred under the experimental conditions, the peptide mass was determined using eq 1

where D is the adjusted deuterium incorporation, m is the experimentally observed mass
at a given time, m0% is the 0% or undeuterated control, m100% is the fully deuterated
control, and N is the total number of exchangeable amide protons (and excludes the Nterminal proton and any proline residues). To obtain the m0% value, 20 μg of protein was
diluted 20-fold in the quench buffer followed rapidly by the addition of an equal amount
of exchange buffer in D2O and digested with pepsin as described above. Thus, the final
composition of deuterium in the quench and dilution solutions was identical for the

32
samples and the corresponding m0% control. To obtain the m100% value, a fully
deuterated sample was prepared by incubating 20 μg of the protein overnight at room
temperature in an 8 M guanidinium hydrochloride solution prepared in D2O. The protein
sample was subsequently diluted 10-fold with 100 mM ammonium phosphate, pH 2.2 (at
which concentration the denaturant does not interfere with proteolytic digestion), prior to
pepsin treatment. On average, ~25% of the deuterium was lost due to back exchange.

Figure 2. A. Sequence coverage of human cystathionine β-synthase obtained by MS
analysis is shown in red. B. Limited proteolysis of human cystathionine β-synthase.
Cystathionine β-synthase (5 nmol) was incubated at 37 °C with 750 units of porcine
trypsin in 50 mM ammonium bicarbonate buffer, pH 8, in the absence (upper) or
presence of 32 μM AdoMet (lower) for 0 s, 15 s, 30 s, 1 h, 2 h, and 4 h, respectively. The
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reaction was quenched with 1 mM TLCK. The peptide mixture was resolved by 10%
SDS PAGE and visualized by Coomassie blue staining.
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Table 1. Cystathionine β-synthase peptides detected by mass spectrometry
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HPLC-ESI Mass Spectrometry. LC/ESI-MS was employed to determine the extent of
deuterium incorporation into individual peptides. The HPLC injection loop,
chromatographic buffers, and all the tubing used in the LC-MS set up were submerged in
ice to minimize deuterium loss in this step. The peptic peptides were separated by
reversed phase HPLC using a microbore C18 column (5 cm length ×1 mm internal
diameter, Micro-Tech Scientific, Cousteau Court, CA). The solvents used for separation
were A (water, 0.3% formic acid) and B (acetonitrile, 0.3% formic acid). The gradient
was 10-35% solvent B over 20 min at a flow rate of 40µl/min. Peptides were initially
identified by tandem ESI-MS/MS sequencing. The masses of individual peptides in
hydrogen exchange experiments were determined by ESI MS on a Quadrupole Time-ofFlight mass spectrometer (Applied Biosystems). The peak for each peptide was integrated
to obtain a centroid value using the Magtran computer program (17). The deuterium
incorporation for each peptide was quantified by calculating the difference between the
centroid values before and after deuterium exchange at a given time point using eq 1.
Modeled Structures. A model for the regulatory domain of human cystathionine βsynthase extending from residues 411-551 was calculated using SWISS-MODEL (18)
using

the

120

amino

acid

long

CBS

domain-containing

protein

from

Methanothermobacter thermautotrophicus (Archae), strain delta H (PDB-ID 1PBJ). A
docking model for the interaction between the known structure of the dimeric catalytic
core (1M54) and the modeled structure of one regulatory domain was generated using
ZDOCK, which combines pairwise shape complementarity with desolvation and
electrostatics for scoring unbounded docking models (19). The search returned 3600
docking positions, with scores ranging from 62.29 to 30.09. To generate a model of the
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full-length dimer, the single regulatory domain obtained from the docked model was
rotated around the noncrystallographic C2 symmetry axis of the A and B chains of the
catalytic domain. To narrow down the number of docked candidates, the following filter
was applied: that the CR of one of the exposed residues in the 356-370 peptide in the
catalytic domain (358, 359, 362, 363, 365, 366 or 369) is within 4.5-6 Å of any CR in the
regulatory domain. Of the top thirty hits on the score chart, only five satisfied this
criterion and the remaining models were excluded. The five candidates fell into two
groups with the top two and bottom three models being very similar with respect to their
overall disposition of the catalytic and regulatory domains. The bottom three models
placed the regulatory domains at two ends of the dimer, making it difficult to envision
them as surfaces for tetramerization. Of the two top candidates (with the 2nd and 6th
highest scores in the original list of 3600 hits), one (# 6) was selected for further analysis
because it afforded more favorable interactions between the dimers at the presumed
dimer-dimer interface. In this model, the distance between the last structured residue in
the C-terminus of the catalytic domain (CR of K395) and the first structured residue in
the N-terminus of the regulatory domain (CR of Q414) is 49.1 Å, a distance that can
potentially be connected by the 20 intervening amino acids.

2.4 Result and discussion
Cystathionine β-synthase is poised at a critical metabolic junction where the decision
to conserve homocysteine in the methionine cycle or to commit it to transsulfuration is
made. It is therefore not surprising that the enzyme is subjected to complex regulation,

37
which includes intrasteric inhibition imposed by the C-terminal domain and allosteric
activation induced by AdoMet (4). Curiously, a subset of pathogenic cystathionine βsynthase mutations have been described that map to the regulatory domain, display a
higher level of basal activity, but are unresponsive to AdoMet (13, 14). This apparently
paradoxical phenotype associated with pathogenic mutations is enigmatic and begs the
question as to why they are correlated with disease. Structural insight into these
regulatory modes is limited by the availability of the crystal structure of only the
truncated, dimeric form of the enzyme lacking the regulatory domain. Hence, the relative
juxtaposition of the regulatory and catalytic domains and the location of the dimer-dimer
interface in the full-length enzyme are unknown. Kinetic studies indicate that the wildtype enzyme equilibrates between at least two conformations, the “basal” state and the
“activated state”, which is induced by AdoMet (Figure 1) (14). Limited proteolysis of
wild-type cystathionine β-synthase in the presence and absence of AdoMet reveals
differences in the kinetics of degradation of the protein (Figure 2), consistent with a
conformational alteration. Thus, AdoMet stabilizes cleavage of the enzyme at the
hypersensitive site between the catalytic and regulatory domains that converts the fulllength 63 kDa subunit to a truncated 45 kDa one. The pathogenic D444N mutant exhibits
a kcat that is similar to the “activated” state of wild-type enzyme, albeit in the absence of
AdoMet, while the truncated dimer exists in a “superactivated” state, with a kcat that is
~4-fold higher than that of the “basal” state (Figure 1). The D444N mutation increases
the Kd for AdoMet binding to the regulatory domain from 34 ± 2 μM to 510 ± 70 μM
consistent with the observed insensitivity of the mutant to physiological concentrations of
the allosteric effector (11). Hydrogen exchange MS was employed to assess whether
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these discrete kinetic states could be correlated to conformational ones and to localize
peptides that are sensitive to binding of AdoMet and to deletion of the regulatory domain.
AdoMet-Induced Changes in Hydrogen Exchange Kinetics. The effect of AdoMet on the
extent of deuterium incorporation was monitored over a 5 to 60 s time range. Analysis of
the mass distribution profiles of > 50 peptides revealed a very focal conformational
difference. The uncertainty in our mass measurements is ~ 0.2-0.3 deuteriums, and the
difference in deuterium incorporation in all but one of the peptides from the two forms of
the cystathionine β-synthase, fell within this range. Only a single peptide extending from
residues 511-531 was identified that was sensitive to the presence of AdoMet (Figure
3B). A significant shift in the average mass from 2503.36 (-AdoMet) to 2498.24
(+AdoMet) was observed for this peptide indicative of either lower solvent accessibility
or reduced hydrogen bonding in the presence of AdoMet. This represents a decrease in
deuterium incorporation, from 85.5% to 51.6%, relative to the maximum deuterium
incorporation possible for this peptide. The observed binomial distribution of isotope
peaks for this peptide, which is characteristic of EX2 or “uncorrelated exchange”
indicates that a high level of structural homogeneity exists during the deuterium
exchange-in time (20). In other words, the unimodal distribution of the peptide mass
envelope in the presence or absence of AdoMet indicates that under the present
experimental conditions, the enzyme is seen to populate either the “basal” or the
“activated” state and an equilibrium mixture between these two states is not detected.
This is in contrast to the hematopoietic cell kinase SH3 domain in which interconverting
conformers are detected by hydrogen exchange MS (21). Two limitations of the hydrogen
exchange MS approach that are also pertinent to this study bear note. First, differences in
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deuterium exchange kinetics of peptides that occur on a fast time scale (<5 s) would have
been missed in this study. Second, although the 76% coverage of amino acids obtained in
this experiment is relatively high, differences in the remaining 24% of the protein are
missed. Approximately half of the missing residues that we were unable to detect reside
in a protease resistant region of the protein, as discussed under Methods, with most of the
remainder being in the N-terminal heme domain.
The D444N Mutant is Conformationally Locked in the “Activated” State. Since the
pathogenic D444N mutant is unresponsive to physiological concentrations of AdoMet
(14), the mutation could in principle have locked the protein in either the “basal” or the
“activated” conformation. To distinguish between these two possibilities, the kinetics of
hydrogen exchange for the D444N mutant were compared to that of wild type enzyme.
They were found to be virtually identical to that of wild-type enzyme in the presence of
AdoMet (Figure 3B). Thus, the D444N is locked in the “activated” conformation in the
absence of AdoMet binding, which is consistent with its high basal activity and its
insensitivity to physiological concentrations of AdoMet (Figure 3).
Modeled Structure of the C-Terminal Regulatory Domain. Conformational perturbation
of the 511-531 peptide is particularly interesting since it is located in the C-terminal
module of the enzyme (Figure 1) where AdoMet is predicted to bind (11). This module
harbors a tandem repeat of two CBS domains, a secondary structure motif that is
predicted to adopt a β-α-β-β-α fold and is found in diverse proteins in all three kingdoms
of life (22). This domain, which derives its name from its presence in cystathionine βsynthase, is believed to function as an energy-sensing module and typically binds
nucleotides (11). Since the structure of the full-length cystathionine β-synthase is
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unavailable, we have generated a homology modeled structure of the C-terminal
regulatory domain (Figure 3C) using the coordinates for a CBS domain protein from M.
thermoautotrophicus. Pairs of CBS domains are known to dimerize to form a stable
globular domain, which is also the case in the modeled structure for the cystathionine βsynthase C-terminal domain. The 511-531 peptide resides in the CBS2 domain and
exhibits sensitivity to AdoMet binding and also to the D444N mutation in the CBS1
domain. The sensitivity of the 511-531 peptide could be a consequence of its proximity to
the binding site for AdoMet and/or its location on the pathway of allosteric signal
transduction, a distinction that cannot be made by the hydrogen exchange MS approach.

Figure 3. Mapping allosteric effects. A. Comparison of the mass analysis of the 511-531
peptide after 30 s of hydrogen exchange in wild-type enzyme without (upper) and with
(middle) AdoMet and in the D444N mutant lacking AdoMet (lower). B. Location of the
513-531 peptide (in navy) in the modeled structure of the C-terminal domain. The CBS1
and CBS2 domains are shown in red and blue, respectively, and the model extends from
residues 413-544 of cystathionine β-synthase.
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Identification of Peptides That Respond to Deletion of the Regulatory Domain. CTerminal truncation leads to a change in the oligomerization state from R4 to R2 and
generates a “superactivated” form of the enzyme (Figure 1). This form is observed
physiologically in response to a proinflamatory challenge induced by TNFR or
lipopolysaccharide and increases the flux of homocysteine through cystathionine βsynthase, leading eventually to increased synthesis of the antioxidant, glutathione (10).
Surprisingly, deletion of the regulatory domain leads to very focal changes in the kinetics
of deuterium exchange within the time frame of our observations, which extended from 5 s
to 21 h. Only two peptides, contiguous in sequence space, displayed significant
differences in deuterium incorporation (Figure 4A-D). The first peptide extends from
residues 356-370 (Figure 4E). Several amino acids in this segment are quite surfaceexposed, particularly residues 358, 359, 362, 363, 365, 366, and 369. It is interesting to
note that several pathogenic mutations have been reported in this stretch of cystathionine
β-synthase including one, R369C/ H, which is surface exposed in the dimeric structure
(12). A maximum difference in deuterium incorporation in this peptide was seen after a 1
min exposure to D2O (Figure 4B). The centroid mass shifted from 1635.234 (full-length)
to 636.528 in the truncated enzyme, which represents a change from 25% to 41% of
maximal deuterium incorporation seen for this peptide. The second peptide, extending
from residues 371-385, is largely buried and resides at the interface between the
monomers (Figure 4F). Only residues 382-384 in this peptide are surface-exposed and are
located at the base of a cavern. A maximum mass difference in this peptide is observed
after 10 min of exposure to D2O (Figure 4D). The centroid mass shifted from an average
of 1788.969 (full-length) to 1791.342 (truncated), which represents an increase from 25%
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to 52.1% of the maximal deuterium incorporation seen for this peptide. Several patient
mutations have been identified in this stretch of cystathionine β-synthase, including one,
K384N/E that is exposed in the dimeric structure (12).

Figure 4. Mapping intrasteric effects. A. Comparison of the kinetics of hydrogen
exchange of peptides 356-370 (A) and 371-385 (B) that respond to deletion of the
regulatory domain. The spectra in A and B represent samples that were quenched after 1
min. C and D show the differences in the kinetics of deuterium incorporation in the 356370 peptide in the truncated (circles) and full-length (triangles) protein (C) and for the
371-385 peptide in truncated (circles) and full length (triangles) protein (D). The closed
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and open symbols represent data from two independent experiments. E. Location of the
356-370 and 371-385 peptides (in navy) in the crystal structure of the catalytic core
shown in surface representation. The subunits are shown in gray and blue, and the
residues, P78 and K102, that are mutated in some homocystinuric patients and lead to
lack of AdoMet sensitivity are shown in yellow. F. A different view of the truncated
dimer highlighting the location of the 371-385 peptide.

A Modeled Structure for Full-Length Cystathionine β-Synthase. The hydrogen exchange
data identifies two surfaces in the dimeric structure that experience greater solvent
accessibility or reduced hydrogen bonding interactions upon deletion of the regulatory
domain (Figure 4E and 4F). We have employed the MS data in conjunction with the
reported properties of cystathionine β-synthase to guide our selection of a model for the
full-length enzyme (Figure 5) generated by the ZDOCK program. It is important,
however, to first note some limitations of this model-building exercise. In principle, it is
possible that the peptides identified in this study report indirectly on the loss of the
regulatory domain with a consequent change in the oligomeric organization, and that the
actual interaction surfaces were missed due to the time course of the kinetic analysis.
Hydrogen exchange rates for individual amides in a protein can vary over several orders
of magnitude (23), and only those amides with half-lives for exchange that are similar to
the experimental labeling time report on structural changes (20). Thus, a limitation of this
study is that hydrogen exchange kinetics were monitored in a time range from seconds to
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hours, and differences in dynamics and/or structure that resulted in differences in
deuterium incorporation rates on a shorter time scale would have been missed. We
propose that both the 356-370 and the 371-385 peptides are likely to be reporting on
deletion of the regulatory domain based on the following lines of reasoning.
Cystathionine β-synthase exists as a homotetramer that separates into dimers following a
proteolytic clip between the catalytic and regulatory domains (16). Thus, interactions
between the regulatory domains appear to be more important in preserving the tetrameric
structure than interactions between the catalytic domains. We propose that the 356- 370
peptide is involved in making direct contact with the regulatory domain based on its
proximity to the P78 and K102 residues (Figure 4E). Mutations in these two residues
(P78R/K102N) are inherited as linked pathogenic mutations in homocystinurics (12). The
P78R/K102N mutations impair sensitivity to AdoMet, suggesting their proximity to the
regulatory domain (Sen and Banerjee, manuscript in preparation). The docked model
generated by ZDOCK provides an excellent fit to our assignment of this region as the
regulatory-catalytic domain interface (Figure 5 A). The exposed surface of the 371-385
peptide is located at the bottom of a cavity (Figure 5A) and leads to a short helix that
ends in a loop representing the C-terminus of the catalytic domain. In the intact structure,
this loop would lead to the regulatory domain and its truncation could perturb the
environment of the 371-385 peptide, resulting in changes in the kinetics of deuterium
incorporation. The location and the limited surface exposure of this largely buried peptide
appear to be incompatible with its possible involvement in the dimer-dimer interface
(Figure 5). Based on the docked model of the dimer, we propose a schematic model for
the organization of the full-length enzyme (Figure 5B). In this model, the regulatory
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domains on adjacent monomers are on opposite edges of the dimer and contact the mirror
domains in the tetramer. This model is consistent with the known properties of the wild
type and mutant enzymes, the role of the regulatory domain in tetramerization, and with
the separation of dimers following deletion of this domain. In this model, the regulatory
domains form the dimer-dimer interface and generation of the truncated dimer exposes on
the catalytic domain only those surfaces that are sensitive to loss of the regulatory
domain. This is consistent with our ascription of the sensitivity of both the 356-370 and
371-385 peptides to deletion of the regulatory domain. The validity of this model will of
course be tested as additional insights into cystathionine β-synthase are gained and
ultimately by the crystal structure of the full-length enzyme itself.

Figure 5. Modeled structure of full-length cystathionine β-synthase. A. A docked model
showing the predicted juxtaposition of the regulatory domains and the catalytic core of
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the dimer. The two catalytic domains are shown in light gray and light blue, respectively,
while the corresponding regulatory domains are shown in darker shades. The light blue
subunit is behind the plane of the light gray subunit and not visible. A portion of the 356370 peptide (in navy) on one of the chains and of the heme (in red) are visible in this
view. This model was generated using ZDOCK as described under Methods. B. Model of
the full-length cystathionine β-synthase showing the relative juxtaposition of two R2
dimers. The color scheme used in A is retained.

2.5 Conclusions
In summary, we have localized focal conformational changes in wild-type
cystathionine β-synthase that are induced by AdoMet, to a peptide which spans residues
511- 531 in the regulatory domain. Furthermore, we have demonstrated that this
“activated” conformation is mimicked by the pathogenic D444N mutation, explaining its
known insensitivity to AdoMet (14, 24). This approach could be useful for providing
structural insights into other pathogenic mutants. The kinetics of hydrogen exchange
reveal two surfaces that are sensitive to deletion of the regulatory domain. This
information has been used to build a structural model of the full-length human enzyme
(Figure 5), which could be helpful in providing a framework for understanding the
interactions between the regulatory and catalytic modules and the penalties associated
with pathogenic mutants.
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Chapter 3
A pathogenic Linked Mutation in the Catalytic Core of Human
Cystathionine β-Synthase Disrupts Allosteric Regulation and Allows Kinetic
Characterization of a Full-Length Dimer
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3.1 Abstract
Cystathionine β-synthase catalyzes the condensation of serine and homocysteine to
yield cystathionine and is the single most common locus of mutations associated with
homocystinuria. In this study, we have examined the kinetic consequences of a pair of
linked patient mutations, P78R/K102N, that are housed in the catalytic core of the protein
and compared it to the effects of the corresponding single mutations. The P78R mutation
affords purification of a mixture of higher order oligomers, P78R-I, which resembles the
mixed quaternary state associated with wild type enzyme. However, unlike wild type
enzyme, P78R-I converts over time to P78R-II, which exists predominantly, as a fulllength dimer. The specific activities of the K102N, P78R-I and P78R-II mutants in the
absence of AdoMet are ~3-, 9- and 3-fold lower than of wild-type enzyme and are
stimulated 2.9-, 2.5- and 1.4-fold respectively by AdoMet. However, when linked, the
specific activity of the resulting double mutant is comparable to that of wild-type enzyme
but it is unresponsive to AdoMet, revealing that interactions between the two sites
modulate the phenotype of the enzyme. Steady-state kinetic analysis for the double
mutant reveals a sigmoidal dependence on homocysteine that is not observed with wildtype enzyme, which is ascribed to the mutation at the K102 locus and indicates changes
in subunit interactions. Hydrogen-deuterium mass spectrometric analyses reveals that
even in the absence of AdoMet, the double mutant is locked in an activated conformation
that is observed for wild-type enzyme in the presence of AdoMet, providing a structural
rationale for loss of this allosteric regulation. To our knowledge, this is the first example
of mutations in the catalytic core of cystathionine b-synthase that result in failure of
AdoMet-dependent regulation. Furthermore, analysis of individual single mutations has
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permitted for the first time, partial kinetic characterization of a full-length dimeric form
of human cystathionine β-synthase.

3.2 Introduction
Cystathionine β-synthase is a pyridoxal phosphate (PLP)1-dependent protein that
catalyzes the condensation of serine and homocysteine to give cystathionine and is
activated by the allosteric effector, AdoMet (1-3). It catalyzes the first step in the
transsulfuration pathway connecting the methionine cycle to cysteine production.
Mutations in cystathionine β-synthase are the single most common cause of hereditary
hyperhomocysteinemia and over one hundred pathogenic mutations have been described
so far (4). They represent a roadmap of residues that are important for the structural
and/or functional integrity of the enzyme and characterization of these mutants have
begun to provide invaluable insights into the organization and regulation of this unusual
enzyme (5-9). The pathogenic mutations are dispersed over all three domains of the
modular protein: the N-terminal heme domain, which is found in some but not all
eukaryotic cystathionine β-synthases, the central active site domain where PLP is bound
and the C-terminal regulatory domain, which is required for allosteric activation of the
enzyme by AdoMet.
The purified human enzyme is a homooligomer with a subunit mass of 63 kDa and
exists in multiple higher order oligomeric states ranging from a dimer to a 16-mer (10),
which have not been purified and characterized separately to date (Figure 1). A
hypersensitive site leads to the facile proteolytic separation between the catalytic core and
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the regulatory domain (11). The resulting truncated enzyme is a well-behaved dimer that
is not prone to aggregation unlike the full-length enzyme. It has a subunit mass of 45 kDa
and exhibits an ~4-fold higher kcat than the full-length form (9) but is unresponsive to
AdoMet (12). The regulatory domain thus appears to be autoinhibitory and its cleavage
alleviates inhibition of cystathionine β-synthase activity (11-13). Furthermore, truncation
is accompanied by a change in the oligomerization state of the protein from tetramer to
dimer. These results reveal a complex role for the C-terminal domain in mediating
regulation of cystathionine β-synthase including intrasteric and allosteric regulation and
in the oligomerization of the protein beyond the dimeric state.

Figure 1. Model of the oligomeric heterogeneity seen with human cystathionine βsynthase. It is not known whether the equilibrium between the different oligomeric states
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involves dissociation into monomers and has been shown for simplicity, to involve either
the dimer or the tetramer. The P78R mutation shifts the equilibrium towards the fulllength dimer compared to wild type enzyme. Deletion of the regulatory domain leads to a
truncated dimer.

A class of pathogenic mutations housed in the regulatory domain has been described
that display a common and seemingly paradoxical phenotype (6, 9, 14, 15). When
mimicked in vitro, these regulatory domain mutants are unresponsive to activation by
AdoMet but exhibit robust enzyme activity comparable to or greater than that of wild
type enzyme (6, 9). Mathematical modeling of methionine metabolism provides a
rationale for the build up of homocysteine by the mere loss of allosteric activation of
cystathionine β-synthase, particularly under conditions of methionine excess, confirming
an important role for AdoMet-dependent regulation in intracellular homocysteine
homeostasis (16).
The crystal structure of the catalytic core of cystathionine β-synthase has been
reported and reveals the relative juxtaposition of the heme- and PLP-domains (17, 18).
However, the structure of the regulatory domain and its interaction with the catalytic core
are unknown. The C-terminal domain is comprised of a tandem repeat of two CBS
domains, a β-α-β-β-α secondary structure motif that is found in diverse proteins in all
three kingdoms of life and believed to function as an energy sensor (19, 20). A
homology-modeled structure of the catalytic core has been generated based on the crystal
structure of a CBS-domain containing protein from Methanobacter thermoautotrophicus
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(21). The only structural insights that are presently available on the mechanism of
allosteric signal transduction between the regulatory and the catalytic domain derives
from hydrogen exchange MS studies, which identified a single peptide in the CBS2
domain extending from residues 511-531 that exhibits a lower propensity for deuterium
incorporation in the presence of AdoMet (21). In combination with other hydrogen
exchange MS data, these studies have been used to build a docked model of the
regulatory and catalytic domains (Figure 2) (21), which in the absence of a crystal
structure for the full-length enzyme, provides a useful framework for interpreting the
functional data (22). Although the regulatory domain is believed to house the binding site
for AdoMet (20), the role of the CBS domains in cystathionine β-synthase, the protein
from which this motif derives its name, is unknown.
In this study, we report on the characterization of a linked patient nucleotide
mutation, C233G/G306C, corresponding to P78R/K102N in the polypeptide, which are
located in the catalytic core of the protein (Figure 2). These paternally inherited cis
mutations have been described in three siblings who, like most homocystinurics, are
compound heterozygotes, and have a maternally inherited E239K mutation in the other
allele (23). Interestingly, the siblings display a wide range of clinical phenotypes from
severe (in the two sisters) to benign (in the brother) despite sharing an identical genotype
at this locus, which indicates possible gender-dependent modulation of the expression of
cystathionine

β-synthase-dependent

homocystinuria.

Previous

studies

of

the

P78R/K102N mutation were limited to cell lysates of Escherichia coli expressing
recombinant cystathionine β-synthase (23). We have analyzed, using purified
recombinant human cystathionine β-synthase, the biochemical penalties associated with
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the individual mutations to elucidate the contribution of each locus to the phenotype of
the double mutant. The P78R mutation allowed for the first time, limited kinetic
characterization of a full-length dimeric form of cystathionine β-synthase. Interestingly,
interactions between the K102N and P78R mutations result in a compound phenotype
that is similar to but also distinct from those of the single mutants. The double mutant is
as active as the wild-type enzyme but is unresponsive to the allosteric activator, AdoMet.
The loss of allosteric regulation is explained by hydrogen exchange MS data, which
revealed that the linked mutation locks the protein in a conformation achieved by wildtype enzyme in the presence of AdoMet. To our knowledge, this is the first example of
mutations in the catalytic core that confer AdoMet insensitivity, exhibit high basal
activity and thus resemble a subset of regulatory domain mutations that have been
described in homocystinuric patients.
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Figure 2. Modeled structure of full-length cystathionine β-synthase dimer showing
locations of the P78 and K102 residues. The structure was generated by docking the
crystal structure of the catalytic core of cystathionine β-synthase (in tan) with the
homology modeled structure of the regulatory domain (in scarlet) as described previously
(21). The locations of P78 and K102 (in blue ball and stick representation) are indicated
as are of the heme (in red) and PLP (in blue).
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3.3 Material and methods
D, L-homocysteine were purchased from Sigma. [14C]-

Materials-Serine, IPTG, and

Serine (158 mCi/mmol) was purchased from Amersham. GST Sepharose and SuperdexTM
200 were purchased from Pharmacia. Deuterium oxide (100.00 atom % D) was purchased
from Sigma. AdoMet 1,4-butanedisulfonate was a generous gift from Knoll Farmaceutici
Spa (Milano, Italy). Thrombin was purchased from GenTrac Inc. Middleton, WI.
Complete tablets (protease cocktail inhibitors) were purchased from Roche Diagnostics
(Mannheim, Germany).
Generation of the CBS Mutants and Protein Purification-The single mutants K102N,
P78R and the double mutant P78R/K102N, were generated by site-directed mutagenesis
using the Quick Change Kit from Stratagene. The template for mutagenesis was
pGEX4T1/hCBS containing wild-type human cystathionine β-synthase gene fused inframe with glutathione S-transferase (24). The forward and the reverse primers that were
employed were:
P78R:

Sense:

5' :CCAAAATCTTGCGAGATATTCT

Antisense: 5': AGAATATCTCGCAAGATTTTTGG
K102N: Sense:

5': AAGTTCGGCCTGAACTGTGAGCTCTTGGC

Antisense: 5': GCCAAGAGCTCACAGTTCAGGCCGAACTT
The double mutant, P78R/K102N, was constructed by introducing the P78R mutation
using the single mutant, K102N as template, and the appropriate set of primers. The
mutations were confirmed by nucleotide sequencing at the Genomics Core Facility at the
University of Nebraska Lincoln.
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Protein purification and enzyme assays- The mutant enzymes were expressed in E. coli
and purified as glutathione S-transferase fusion proteins using recombinant expression
systems essentially as described for wild-type enzyme (24). The cell extract was prepared
and sonicated in 50 mM Tris HCl pH 8, supplemented with protease inhibitor cocktail
tablets (Roche Diagnostics). One tablet was used for the 300 ml cell extract prepared
from a 6 l culture.
Following partial proteolysis by thrombin (1 U/mg protein) to remove the GST tag,
the K102N and P78R/K102N mutants were dialyzed to remove glutathione and purified
by anion exchange chromatography as described previously (24). The P78R mutant was
purified following thrombin digestion by gel filtration chromatography using a 90 X 3 cm
Superdex TM 200 column eluted isocratically with 50 mM Tris HCl containing 0.1 M
NaCl. Over 50 mg of ~90% pure protein was obtained from 6 l of culture for each
mutant.
The enzyme activity was assayed under aerobic conditions using 30 mM [14C]-serine
and 30 mM D,L-homocysteine as described previously (13). One unit of enzyme activity
catalyzes the conversion of 1 µmol cystathionine min-1 at 37˚C. Protein concentration
was determined by the Bradford method using bovine serum albumin as a standard. The
concentration of the stock homocysteine solution was determined immediately prior to
the experiments by titration with 5,5'-dithiobis 2-nitrobenzoic acid and estimated using a
value of ε412 of 13,600 M-1 cm -1.
Steady-state kinetic analysis was performed in the standard radiolabeled assay and
initiated by addition of homocysteine. The reaction mixture was incubated for 30 min at
37˚C and terminated by the addition of 200 μl of 10% trifluoroacetic acid. The
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radiolabeled product, [14C]-labeled cystathionine, was separated from [14C]-labeled serine
as described previously (13). The kinetic sbehavior of some mutants (indicated in Table
I) showed a sigmoidal rather than a hyperbolic dependence on substrate concentration
and these data were fitted to the Hill equation to obtain the Hill coefficient.
Hydrogen-deuterium exchange mass spectrometry- These experiments were performed
with wild type and the P78R/K102N forms of cystathionine β-synthase exactly as
described previously (21). To correct for loss of deuterium incurred under the
experimental conditions, the peptide mass was determined using equation 1 where D is
the adjusted deuterium incorporation, m is the experimentally observed mass at a given
time, m0% is the 0 percent or undeuterated

D=

(m − m0% )
(m100%−m 0% )

XN

Equation 1

control, m100% is the fully deuterated control and N is the total number of exchangeable
amide protons (and excludes the N-terminal proton and any proline residues). To obtain
the m0% value, 20 µg of protein was diluted 20-fold in the quench buffer followed rapidly
by the addition of an equal amount of exchange buffer in D2O and digested with pepsin
as described above. Thus, the final composition of deuterium in the quench and dilution
solutions was identical for the samples and the corresponding m0% control.
To obtain the m100% value, a fully deuterated sample was prepared by incubating 20
µg of the protein overnight at room temperature in an 8 M guanidinium hydrochloride
solution prepared in D2O. The protein sample was subsequently diluted 10-fold with 100
mM ammonium phosphate, pH 2.2 (at which concentration the denaturant does not
interfere with proteolytic digestion), prior to pepsin treatment.
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HPLC-ESI Mass Spectrometry- LC/ESI-MS was employed to determine the extent of
deuterium incorporation into individual peptides as described previously (21). The
masses of individual peptides in hydrogen exchange experiments were determined by
ESI-MS on a Quadrupole time-of-flight mass spectrometer (Applied Biosystems). The
peak for each peptide was integrated to obtain a centroid value using the Magtran
computer program (25). The deuterium incorporation for each peptide was quantified by
calculating the difference between the centroid values before and after deuterium
exchange at a given time point using equation 1.
Native gel electrophoresis for determining oligomeric state- Protein samples (30 µg each)
were separated on a 4-20% gradient gel under nondenaturing conditions. The gels were
run at 4˚C at 120 V and 15 mA current.

3.4 Results
Purification and Oligomeric States of the K102N, P78R and P78R/K102N Mutants- The
recombinant single and double mutants were obtained in at least 90% purity as
determined by electrophoresis under denaturing conditions and by the ratio of the 280 nm
to 428 nm absorption peak (which is ~1 for pure wild type enzyme (24)). The PLP
content of both the single and the double mutants was identical to that of wild type
enzyme, i.e. one PLP per subunit (data not shown). The P78R single mutant exhibited a
shift in the equilibrium distribution of oligomeric states that was detected by analysis of
freshly purified enzyme. Gel filtration chromatography resulted in elution of P78R as a
broad peak and partial resolution of two species designated hereafter as P78R-I and
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P78R-II respectively, as revealed by native gel electrophoresis (Figure 3). P78R-I
migrated as a mixture of higher-order oligomers, which is also observed with wild-type
enzyme, whereas P78R-II is predominantly in the dimeric state. Storage of P78R-I at 4˚C
for 24-48 h resulted in its conversion to the P78R-II state. In contrast, the K102N and the
double mutant behaved like wild-type enzyme by native gel chromatography and exists
as a mixture of higher-order quaternary states.

Figure 3. The P78R-II mutant behaves like a dimer. Native gel electrophoresis of wild
type cystathionine β-synthase and various single and double mutants shows heterogenous
oligomeric states. P78R-I* refers to the form obtained by overnight incubation of P78R-I
at 4˚C. Lane 1 shows migration of molecular weight markers and lane 8, the truncated
dimeric form of cystathionine β-synthase (T-α2) which has a molecular mass of ~90 kDa.

Kinetic Properties of the K102N, P78R and P78R/K102N Mutants- The steady-state
kinetic parameters for the variants were compared with those of wild type enzyme (Table

64
1). Each of the single mutants diminished the specific activity with the K102N showing a
3-fold lower activity (65 μmol mg-1 h-1) and the P78R-I and P78R-II forms exhibiting 9(19 μmol mg-1 h-1) and 3-fold (62 μmol mg-1 h-1) lower activity than wild type enzyme
(178 μmol mg-1 h-1). Overnight storage of P78R-I at 4˚C resulted in its conversion to
P78R-II and was accompanied by a 3-fold increase in specific activity to 58 ± 5 μmol
mg-1 h-1. Interestingly, the deficits in activity associated with each of the single mutations
were negated in the double mutant (169 μmol mg-1 h-1), which was as active as wild-type
enzyme in the absence of AdoMet.
Some changes were observed in the kinetic parameters for the substrates. The KM for
serine is ~2-fold higher for the K102N and P78R/K102N mutants and ~4-fold higher for
the P78R-II mutant compared to wild-type enzyme. A sigmoidal dependence of activity
on serine concentration was seen with P78R-I with a Hill coefficient of 2.4. Sigmoidal
kinetics are observed with the K102N single and the P78R/K102N double mutants when
homocysteine is the variable substrate with a Hill coefficient of 3, indicating positive
cooperativity. The KM for L-homocysteine is 2-fold higher for the K102N mutant, lower
for the P78R-II mutant, and comparable to wild-type enzyme for the double mutant
(Table I).
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Table 1. Comparison of kinetic parameters of the single and double mutants with wildtype cystathionine β-synthase

Enzyme

Wild type

P78R-I

P78R-II

K102N

K102N/P78R

S.A.a(+AdoMet)

378 ± 17

47 ± 4

84 ± 2

185 ± 4

169 ± 9

kcatb (+AdoMet)

6.6 sec-1

0.8sec-1

1.4 sec-1

3.0 sec-1

3.0 sec-1

19 ± 2

62 ± 0.5

65 ± 9

169 ± 9

3.0 sec-1

0.3 sec-1

1.0 sec-1

1.0 sec-1

3.0 sec-1

2.0 ± 0.3

1.9 ± 0.2

8±3

3.8 ± 0.8

5.1 ± 0.8

Hill Coefficient

-

2.4 ± 0.7

-

-

-

KMHcy (mM)

5.0 ± 0.9

5±2

2.4 ± 0.5

10 ±1

4.4 ± 0.3

Hill Coefficient

-

-

-

3 ±1

3.0 ± 0.2

S.A. (-AdoMet)
kcat (-AdoMet)
KMSer (mM)
c

178 ± 5

a

Specific activity is in units of µmol cystathionine formed h-1 mg-1 protein.

b

kcat is calculated based on the molecular mass of the monomer. Hill coefficients
are reported only when a sigmoidal dependence on substrate concentration was
observed. In all other instances, the KM values were obtained by MichaelisMenten analysis of the data set.

The P78R/K102N Mutant is Insensitive to Allosteric Regulation. In the presence of
AdoMet, the specific activity of wild-type cystathionine β-synthase increases ~2-fold
from 178 μmol mg-1 h-1 to 378 μmol mg-1 h-1 (24). The K102N and P78R-I variants
exhibit sensitivity to AdoMet and were activated 2.9- and 2.5-fold respectively. In
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contrast, P78R-II, which exists predominantly in the dimeric state, shows diminished
activation (1.4-fold) by AdoMet. Based on the densitometric analysis of the native gel,
we estimate that ~30% of P78R-II is present in the higher oligomeric state. Thus, the
AdoMet responsiveness of P78R-II indicates that the full-length dimer is also sensitive to
allosteric regulation. In contrast, the P78R/K102N double mutant is unresponsive to
AdoMet. Thus, interaction between the P78 and K102 positions in the double mutant
results in loss of allosteric regulation.
Hydrogen Exchange MS Reveals Conformational Lock in the P78R/K102N Mutant.
Hydrogen exchange MS was employed to determine if the insensitivity of the double
mutant results from a conformational lock in the kinetically distinguishable “basal” and
“activated” states (Figure 4A). Of the ~50 peptides that were identified for the double
mutant, a significant difference in the extent of deuterium incorporation was observed in
only one peptide, extending from residues 511-531 (Figure 4B) with a mass of 2502.704.
The same peptide in wild-type enzyme had previously been shown to exhibit a downshift
in the centroid mass from 2503.36 in the absence to 2498.24 in the presence of AdoMet
(21). This corresponds to a decrease in maximal deuterium incorporation from 85% in the
wild-type enzyme to 51% in the double mutant. The P78R/K102N double mutant thus
appears to be conformationally locked in the “activated” state, explaining its insensitivity
to AdoMet. The decrease in deuterium concentration upon exposure to AdoMet in wildtype enzyme and in the double mutant as isolated, indicates decreased solvent exposure
and/or hydrogen bonding interaction in this conformation.
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Figure 4. Conformational change induced by AdoMet binding to cystathionine βsynthase. A. Model of an AdoMet-induced conformational change in cystathionine βsynthase. The model correlates differences in kinetic properties associated with the basal
and activated states of cystathionine β-synthase with the structural changes revealed by
hydrogen-deuterium mass spectrometry. The P78R/K102 patient mutation is locked in
the activated conformation even in the absence of AdoMet. B. Mass spectrometric
analysis of wild-type and the P78R/K102N mutants of cystathionine β-synthase.
Hydrogen-deuterium exchange mass spectrometric analysis of cystathionine β-synthase
identified a single peptide extending from residues 511 to 531 that revealed a difference
in the centroid mass after 30 s of hydrogen exchange in the presence (m/z = 624.803)
versus absence (m/z = 625.676) of AdoMet. The same peptide in the double mutant in the
absence of AdoMet, exhibited a centroid mass corresponding to that observed with wildtype enzyme in the presence of AdoMet.
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Discussion
Pathogenic mutations represent Nature’s map of residues that are important for the
structural and/or functional integrity of proteins. In the case of cystathionine β-synthase,
over 100 patient mutations have been described that are dispersed across all three
domains of the modular protein (4). Biochemical characterizations of a limited number of
missense mutations that are remote from the active site have been described (5-9) and
have provided novel insights into clinically important phenotypes associated with specific
mutations, viz. pyridoxine responsiveness. A subset of pathogenic mutations, clustered in
the CBS1 domain of the regulatory module are associated with an interesting phenotype,
i.e. they show robust basal activity but are unresponsive to allosteric activation by
AdoMet (6, 9, 14). Biophysical characterization of one such mutant, D444N, revealed
that it is conformationally locked in an activated state that is observed with wild-type
enzyme only in the presence of AdoMet (21). These studies reveal that AdoMet binding
to the regulatory domain shifts the conformation of cystathionine β-synthase from a
kinetically distinguishable “basal” state to an “activated” state, which in turn, increases
the activity of the enzyme. In this study, we have examined the penalties associated with
a pair of linked mutations P78R/K102N, described in homocystinuric patients and
compared them to the deficits associated with the single mutations.
Wild-type human cystathionine β-synthase exists as a mixture of oligomeric states
with higher-order oligomers being the predominant species. Analysis of wild-type
cystathionine β-synthase by blue native gel electrophoresis reveals the presence of
oligomers ranging from a dimer to ~16-mers (10). However, the kinetic properties
associated with the full-length dimer have not been reported because of the difficulty in
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separating the various oligomeric states in pure form. P78 is located at the periphery of
the dimer interface in the crystal structure of truncated cystathionine β-synthase (22, 26)
(Figure 2). Unlike wild-type enzyme, chromatography of P78R results in partial
separation of two oligomeric states monitored by native gel chromatography, which
correspond to a predominantly full-length dimeric form (P78R-II) and a mixture of higher
oligomeric forms (P78R-I). The P78R-I form is unstable and is converted to the P78R-II
state over 24 h at 4˚C, permitting limited kinetic characterization of the full-length
dimeric form of cystathionine β-synthase (Table 1). The principal findings for P78R-II,
which is enriched in the full-length dimer, is that it is active, albeit ~3-fold less so than
wild-type enzyme, and is responsive to allosteric activation by AdoMet. The KM values
for both serine and homocysteine for P78R-II are similar to those for wild-type enzyme.
The P78R-I form, which is a heterogeneous mixture of oligomeric states is 3-fold less
active than P78R-II and exhibits KM values for the two substrates that are similar to wildtype enzyme. Extrapolating from these results to wild-type enzyme, suggests that a
dimeric form of cystathionine β-synthase would be active and AdoMet responsive. The
physiological relevance of the oligomeric heterogeneity associated with purified human
cystathionine β-synthase is not known, nor what ligands or metabolic state might favor
one versus other structures. Since the full-length dimer of P78R is associated with higher
activity compared to the mixed higher-order oligomeric state, P78R-I, it raises the
possibility that stabilization of the full-length dimer may be used as a mechanism for
upregulation of wild-type cystathionine β-synthase under certain conditions.
The instability of the P78R-I form together with the absence of the homogenous
dimeric form in the P78R-II pool, limited our ability to further characterize their
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oligomeric states by biophysical methods viz. analytical ultracentrifugation, which
yielded variable results. It also raises questions about whether the kinetic properties of the
P78R-II species that we have determined, truly reflect those for the full-length dimer. In
fact, we estimate that ~30% of the P78R-II pool represents higher-order oligomers.
Unfortunately, we have been unable to purify the dimeric form any further using various
chromatographic columns. Nonetheless, the observed differences in the kinetic properties
between P78R-I and -II, particularly with respect to specific activity, lends confidence at
least to the qualitative differences between the dimer and the mixed higher oligomeric
states that are reported in this study.
The principal in vitro biochemical phenotypes associated with the linked patient
mutation, P78R/K102N, are high basal activity comparable to wild-type enzyme and
AdoMet unresponsiveness. The high basal activity exhibited by the P78R/K102N enzyme
indicates that the mutant retains a full complement of PLP. This is curious in light of the
B6-responsive phenotype associated with patients carrying this mutation (23). It is
possible that the B6-responsiveness is associated with the second mutation in these
patients, E239K. We also note the seeming paradox between pyridoxine responsiveness
in patients carrying the I278T mutation in cystathionine β-synthase, which is not
reflected in an altered affinity for PLP in the expressed protein (27). This observation led
the authors of the study to suggest that the clinical response to pyridoxine may involve
multiple mechanisms (27).
Since neither single mutant exhibits this property, we conclude that their interaction
in the double mutant is responsible for this phenotype. The insensitivity of the double
mutant to AdoMet could arise in principle from its inability to bind the allosteric activator
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and therefore be locked in the “basal” conformation or to it being locked in the
“activated” conformation that is seen with wild-type enzyme in the presence of AdoMet
(Figure 4A). The AdoMet responsive peptide identified by hydrogen exchange MS
reveals that in the catalytic domain mutations, P78R/K102N, as in the regulatory
mutation, D444N, the exchange kinetics for this peptide in the absence of AdoMet mimic
that for wild type enzyme, in the presence of AdoMet (Figure 4B). Thus, the double
mutant exhibits an identical conformational signature in a regulatory domain peptide that
is seen with wild type enzyme in the presence of AdoMet or the regulatory domain
mutant, D444N (Figure 4). To our knowledge, this is the first demonstration of mutations
in the catalytic core that mimic the AdoMet insensitivity of a subclass of CBS1-domain
mutations (6, 9).
The K102N mutation exhibits only mild deficits being ~2- to 3-fold less active than
wild type enzyme in the absence or presence of AdoMet (Table 1). The distinguishing
kinetic feature of this mutant is that it exhibits non-Michaelis Menten kinetics when
homocysteine is the variable substrate and the sigmoidal dependence is associated with a
Hill coefficient of 3. This feature is also observed in the double mutant, which exhibits a
KM for homocysteine that is comparable in value to that of wild-type enzyme but exhibits
positive cooperativity with a Hill coefficient of 3. Thus, the change in interaction
between subunits in the double mutant with respect to homocysteine binding can be
ascribed to the missense mutation at the K102 locus. Interestingly, the individual single
mutants are each less active than the double mutant indicating favorable compensatory
changes in the linked pair that restores basal activity to wild-type levels.
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An earlier study had reported preliminary characterization of the single and double
mutants in E. coli cell extracts (23). Both the P78R and K102N single mutants exhibited
fairly variable activity that were 2- to 10-fold lower than wild type enzyme, depending on
the clone. The authors reported seeing no activity with the double mutant. These results
are inconsistent with those reported in this study for the P78R/K102N mutant and also
with the absence of a classical homocystinuric clinical phenotype in one of the siblings in
whom this mutation has been described, especially since the other mutation in this
patient, E239K, has also been reported by the same group to be associated with no
activity in cell extracts (23). The basis of the discrepancy between the two studies is not
known. However, it is interesting to note that other patients with nonclassical
homocystinuria have been described who also have mutations that map to the regulatory
domain of cystathionine β-synthase and result in AdoMet-unresponsiveness (15). These
patients exhibit high plasma homocysteine levels in the absence of the neurological or
connective tissue defects classically associated with homocystinuria due to cystathionine
β-synthase deficiency. This clinical presentation is reminiscent of the male patient with
the AdoMet-unresponsive P78R/K102N double mutation, associated with nonclassical
homocystinuria (23).
Computational studies have revealed that insensitivity to allosteric activation by
AdoMet can result in hyperhomocysteinemia particularly under conditions of high
methionine intake when the transsulfuration pathway becomes especially important in
disposing off excess methionine and homocysteine (16). While the AdoMetunresponsiveness of the P78R/K102N mutation could similarly predispose patients to
hyperhomocysteinemia, the interaction with subunits containing the second mutation
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found in these patients, E239K, may significantly alter the phenotype of the encoded
protein. Alternatively, the nucleotide changes associated with the double mutation could
alter gene expression.
Finally, although known for some time in laboratories that work on this protein, the
oligomeric heterogeneity associated with wild-type cystathionine β-synthase has not been
characterized primarily due to the difficulty in stably resolving the different enzyme
forms. The P78R mutation appears to afford some stabilization of the dimer, which has
permitted the limited characterization reported in this study. It is not known if some or all
of the multiple oligomeric states of cystathionine β-synthase are constructed from
monomers (or dimers) that have slightly different conformations, and therefore qualify as
“morpheeins”, a model for allostery in which the monomer conformation dictates the
resulting oligomeric state (28). The analysis of an uncommon allele of human
porphobilinogen synthase allowed isolation and crystallization of a hexameric form,
distinct from the octamer seen with wild-type enzyme and led to the morpheein concept
(29). Elegant studies have since shown that it is the quaternary structure change rather
than the amino acid change that underlies the differences in the kinetic properties of the
two variants of porphobilinogen synthase (29, 30). We currently have insufficient data to
evaluate whether or not a dynamic morpheein equilibrium is responsible for the multiple
quaternary states of cystathionine β-synthase but note that some of the kinetic attributes
of morpheeins viz. dependence of activity on order of substrate addition and hysteresis,
have been observed with cystathionine β-synthase (13).
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Chapter 4
Redox Potentials of the Heme and CXXC Motif and their Modulation of
Human Cystathionine β-synthase Activity
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4.1 Abstract
Cystathionine β-synthase (CBS) is a heme containing PLP-dependent enzyme that
condenses serine and homocysteine to form cystathionine. CBS is the first enzyme in the
transsulfuration pathway, commits homocysteine to cysteine synthesis, and is subject to
complex regulation. In addition to heme, human CBS has a second putative redox-active
center, a CXXC motif comprising the residues C272-P273-G274-C275, whose role in
regulating enzyme activity is not known. In this study, we have developed a new assay
for CBS that uses a non-thiol substrate analog, homoserine. We demonstrate that in
addition to the heme, the activity of human CBS is influenced by the redox state of the
CXXC motif. Interestingly, the activity of CBS responds reciprocally to the oxidation
state of the two motifs, increasing when the CXXC motif is reduced while decreasing
when the heme is reduced. To resolve this seeming paradox, we have determined the
midpoint redox potentials of the heme in full-length human CBS and the CXXC motif
and found them to be -356 ± 6 mV and -240 ± 4 mV respectively, versus the standard
hydrogen electrode. The reversible formation of a disulfide bridge between C272 and
C275 was demonstrated by mass spectrometry, which also revealed the presence of the
sulfenic acid intermediate state of the CXXC motif. These studies suggest that the
presence of two redox sensors in human CBS can fine tune the response of this protein to
the ambient redox state rendering it maximally active in a potential range where the
CXXC motif is reduced and the heme is oxidized.
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4.2 Introduction
Cystathionine β-synthase (CBS) is a novel pyridoxal 5´-phosphate (PLP)-dependent
heme protein that catalyzes the condensation of serine and homocysteine to cystathionine
(1, 2). CBS has a modular domain structure and consists of an N-terminal domain which
houses the PLP and the heme binding sites along with a second redox active CXXC
motif. The C-terminal domain of the protein contains a tandem repeat of CBS domains,
CBS1 and CBS2, which are believed to be involved in the binding of the allosteric
activator, S-adenosylmethionine (AdoMet) (3). The full-length enzyme exhibits
oligomeric heterogeneity and exists as a mixture of tetramers and higher order oligomers
(4, 5). Limited proteolysis of human CBS generates a more stable truncated dimeric form
missing 143 residues from the C-terminal end and exhibits an ~4 fold higher kcat than the
full-length enzyme (6, 7). TNFα activation of transformed human liver cells also leads to
formation of a truncated CBS dimer demonstrating the physiological relevance of this
form of the enzyme (8).
CBS is located at a metabolic junction where the decision is made to conserve
methionine by salvaging homocysteine to the methionine cycle or to commit it to
cysteine, and it is thus subjected to complex regulation (Fig. 1). AdoMet, which signals
methionine sufficiency, is a V-type allosteric activator and increases the specific activity
of CBS 2- to 3-fold (9). AdoMet also stabilizes CBS, increasing the half life of the
protein in liver (10). The C-terminal domain, to which AdoMet is presumed to bind (11),
imposes intrasteric inhibition, which is alleviated either by its truncation or by binding of
AdoMet (6, 12, 13). In addition to these modes of regulation, CBS is also subjected to
redox regulation (14). Thus, under in vitro conditions, changes in the activity of CBS are
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correlated with changes in the oxidation state of the heme with the protein being ~2-fold
more active under oxidizing conditions. However, the role of the CXXC motif has not
been assessed since the high homocysteine concentrations used in the in vitro assay (30
mM) would reduce the CXXC disulfide if it existed, and mutations of the cysteines in this
motif mimic only the reduced state of the protein (15). One rationale for redox regulation
of CBS is that this protein, by catalyzing the committing step for cysteine synthesis via
the transsulfuration pathway, influences the synthesis of the antioxidant, glutathione (Fig.
1). It is estimated that ~50% of the cysteine incorporated into glutathione in liver
originates from the transsulfuration pathway (16, 17) while the remainder is presumably
derived from extracellular cystine via import and subsequent reduction. The role of CBS
in provision of cysteine is evidenced by the lower cysteine concentration in brain and
liver in a murine knockout model of hyperhomocysteinemia, heterozygous for CBS gene
disruption (18).

Fig 1. The transsufuration pathway links homocysteine and glutathione metabolism.
MS,

BHMT

and

γ-CSase

denote

methionine

methyltransferase and γ-cystathionase respectively.

synthase,

betaine-homocysteine
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The heme in CBS is ~20Å away from the catalytic site where the PLP is bound (Fig.
2) (15, 19). The heme resides within an N-terminal extension of ~70 amino acids, which
is absent in the closely related yeast enzyme (20). CBS binds a single equivalent of heme
b per monomer and H65 and C52 serve as the axial ligands in both the ferric and ferrous
states (15, 19). The heme is not essential for catalysis as evidenced by the retention of
~40 percent of wild-type activity in a hemeless variant of human CBS (21). Despite the
substantial distance from the active site, changes in the heme environment elicited by
binding of exogenous ligands to the heme, or a change in the heme iron’s spin or
oxidation state, affect CBS activity, consistent with a regulatory role for this cofactor (2224). Ferrous CBS can bind small gaseous molecules like CO and NO (24), a property
shared by heme sensor proteins viz. FixL, CooA, and HemeAT (25). Based on these
characteristics, CBS has been postulated to be a redox-regulated heme sensor protein
(15).

Fig 2. A. Structure of the truncated dimeric form of CBS showing the locations of heme
(red), PLP (blue) and the cysteines in the CXXC motif (yellow). B. The relative positions
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of the PLP, heme and the CXXC motif in the crystal structure of CBS-ΔC143. The
numbers represent approximate distances in Å.

The CXXC motif in CBS is approximately equidistant from the heme and PLP
centers being ~20Å away from each (Fig. 2). The CXXC motif is commonly found in the
active sites of the thioredoxin family of proteins and is usually involved in thiol-disulfide
exchange reactions (26). In human CBS, residues C272-P273-G274-C275 comprise the
CXXC motif, which is conserved in several organisms but is missing in the yeast and
Dictyostelium enzymes (1). It is interesting to note that the CXXC motif in thioredoxin is
also comprised of the same sequence of residues i.e., CPGC (26). Two crystal structures
of the truncated dimer of CBS have been reported and the CXXC motif is in the
disulfide-linked state in one and in the dithiol state in the other (14, 19). The crystal
structures reveal that the CXXC motif is accessible to small molecule reductants, e.g.
dithiothreitol, which was used for crystallization of the dithiol form of the enzyme, and
suggests that this motif may be redox active in CBS.
In this study, we have characterized the two redox centers in CBS, the heme and the
CXXC motif, as a first step towards evaluating their potential for redox regulation in the
intracellular milieu. To determine the effect, if any, of the CXXC redox state on CBS
activity, we have developed a new assay in which a nonthiol substrate, homoserine,
substitutes for homocysteine. We have determined the midpoint potentials for the heme
and the CXXC motif in human CBS. Our results suggest that the presence of two redox
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sensitive motifs in CBS may allow for fine-tuning of the redox responsiveness of the
enzyme to the ambient potential.

4.3 Materials and methods
Materials-Serine, Isopropyl β-D-1-thiogalactopyranoside (IPTG), iodoacetic acid (IAA),
dithiotreitol (DTT), methyl viologen, benzyl viologen, anthroquinone 2-sulfonic acid,
trypsin and Glu-C (V8-E) were purchased from Sigma. [14C]-Serine (158 mCi/mmol) was
purchased from Amersham and GST Sepharose from Pharmacia. Thrombin was
purchased from GenTrac Inc., Middleton, WI. Complete tablets (protease cocktail
inhibitors) were purchased from Roche Diagnostics (Mannheim, Germany). Rapigest was
purchased from Waters (Milford, MA). Mal-PEG 5 kD was purchased from Laysan Bio
Inc (Alabama). Mal-PEG 5 kD is usually contaminated with lower molecular weight
components that cause smearing during polyacrylamide gel electrophoresis. To avoid this
problem, the lower molecular weight contaminants were separated from Mal-PEG 5 kD
using a PD-10 desalting column (from Amersham) and 50 mM Tris-HCl buffer, pH 8, for
isocratic elution. All the other reagents were used without further purification.
Purification of Full-Length CBS and the Truncated Dimer-The truncated dimer, CBSΔC143, lacking the C-terminal 143 amino acids, and the full-length wild-type enzyme
were expressed and purified from Escherichia coli BL21 cells (Invitrogen) as described
previously (14) except that reducing agents were omitted from all the steps of the
purification.
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Homoserine Assay for CBS- This assay is a modification of the standard assay described
previously (14), where the natural substrate, L-homocysteine, is replaced by the nonthiol
derivative, L-homoserine (Fig. 3). The enzyme activity was assayed under aerobic
conditions using 30 mM [14C]-serine and 10 mM L-homoserine in the presence or
absence of 20 mM DTT or 20 mM glutathione. The amount of enzyme used in the assay
was 1 µg for the truncated dimer and 5 μg for full-length CBS. One unit of enzyme
activity represents the amount needed for formation of 1 µmol of product•h-1 at 37 °C.
Protein concentration was determined by the Bradford method using bovine serum
albumin as a standard.

Figure 3. Schematic representation of the condensation reaction between serine and
homoserine or the alternate substrate, homoserine, catalyzed by CBS.

Determination of the Redox State of the CXXC Motif by Mass Spectrometry (MS)CBS-ΔC143 (50 µg) in the reduced (with 50 mM DTT) and oxidized (lacking DTT)
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states was treated with IAA (20 mM) for 1 h at room temperature in the dark. Excess
DTT was removed from the reduced sample preceding the alkylation step, by extensive
washing with 10 mM ammonium bicarbonate buffer, pH 8, containing 8 M urea, using a
YM-30 Centricon concentrator (Millipore). The alkylation reaction was quenched by
addition of excess DTT and the samples were diluted 10-fold and washed with 10 mM
ammonium bicarbonate buffer, pH 8 using a YM-30 Centricon concentrator. Proteolytic
digestion was then performed using Glu-C or trypsin at an enzyme to substrate ratio of
1:20 (wt/wt). Rapigest, a mild detergent, was used as per the vendor’s instructions, to
improve sequence coverage. The digestion reaction was carried out for 30 h at 37°C and
the peptides were separated by HPLC on a C18 column (PepMap100, 75 µm x 15 cm, 3µm 100 Å, LC Packings, Sunnyvale, CA) using a gradient of acetonitrile and water. The
solvents used for separation were: A (water with 0.3% formic acid) and B (acetonitrile
containing 0.3% formic acid). The gradient was 10-35% solvent B over 20 min at a flow
rate of 40 µl/min. The masses of individual peptides were determined by ESI-MS on a
Quadrupole time-of-flight mass spectrometer (Applied Biosystems). Peptides were
identified by tandem ESI-MS/MS sequencing.
Spectroelectrochemistry

of

Full-length

CBS-Potentiometric

measurements

were

performed using a two-electrode single compartment spectroelectrochemical cell
containing a gold foil working electrode and a silver/silver chloride reference electrode
(27). The experiments were performed under a nitrogen atmosphere in a Belle
Technology glove box and in a vacuum atmosphere chamber, with <1 ppm oxygen.
Potential measurements are reported relative to the normal hydrogen electrode and were
determined in the reductive and oxidative directions. The experiments were carried out at
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25°C in 50 mM potassium phosphate buffer, pH 7.2. The potentials were determined in
the reductive direction by titrating the enzyme with sodium dithionite (added in
increments of 2 μM). The enzyme concentration was maintained at ~10 μM in a 4 ml
cell. Methyl viologen (10-20 μM), benzyl viologen (10-20μM) and anthraquinone 2sulfonic acid (10 μM) were used as the mediator dyes in the potentiometric experiments.
The potentials for the indicator dyes are as follows: methyl viologen (Eo = -440 mV, pH
7.5), benzyl viologen (Eo = -360 mV, pH 7.5) and anthraquinone 2-sulfonic acid (Eo = 225 mV, pH 7.0). The system was deemed to be at equilibrium in these experiments
when the measured potential change was less than 1 mV in 5 min, and this was typically
achieved within 45 min following addition of dithionite. In the oxidative direction, 5 µM
aliquots of potassium ferricyanide were added to CBS, previously reduced with 75 μM
dithionite. The UV-visible spectra in each experiment were recorded from 300 to 800 nm
on a Cary 100 spectrophotometer. The absorbances at 428 nm and 449 nm were used to
estimate the amount of oxidized and reduced species, respectively. The final spectra were
obtained by subtracting the blank, i.e. spectra of the mediator dyes in the same buffer and
at the same potential from the spectrum of the enzyme. The measured potential was fit to
the Nernst equation (equation 1), where the concentration of the reduced species at a
given potential was obtained by the difference in absorbance at 428 nm or 449 nm from
the spectrum of the fully oxidized form (in the reductive direction).
0.059
E = E + ———
n

[ox]
log ——
[red]

eq. 1

Alkylation with Mal-PEG and Determination of the Midpoint Potential of the CXXC
Motif-Samples of CBS-ΔC143 (50 μg each) in 50 mM Tris-HCl, pH 8, were incubated
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with various ratios of oxidized to reduced DTT for 2.5 h at 37°C. Thereafter, samples
were precipitated with an equal volume of 20% TCA and centrifuged at 13,500 x g for 20
min. The precipitated samples were washed three times with 1 ml of chilled acetone and
then dried. The precipitates were resolubilized with 50 mM Tris-HCl, pH 8, 3% SDS, 1
mM EDTA and 5 mM Mal-PEG. The samples were incubated in this buffer for 10 min at
37°C. The reaction was quenched with excess DTT and centrifuged at 13,500 x g for 20
min to remove any insoluble protein. The cleared samples were then washed extensively
with buffer free of Mal-PEG using YM-30 Centricons (Millipore) to remove excess
alkylating reagent. Thereafter, the samples were mixed with gel loading buffer and
resolved on a 6% polyacrylamide gel using electrophoresis at 30 mA current. The protein
bands were stained with Coomassie blue and the band intensities were estimated with the
imaging software installed in the Gel-Doc instrument (BioRad). The midpoint potential
was -240 ± 4 mV.
Alkylation with Mal-PEG and Determination of the Midpoint Potential of the CXXC
Motif-Samples of CBS-ΔC143 (50 μg each) in 50 mM Tris-HCl, pH 8, were incubated
with various ratios of oxidized to reduced DTT for 2.5 h at 37°C. Thereafter, samples
were precipitated with an equal volume of 20% TCA and centrifuged at 13,500 x g for 20
min. The precipitated samples were washed three times with 1 ml of chilled acetone and
then dried. The precipitates were resolubilized with 50 mM Tris-HCl, pH 8, 3% SDS, 1
mM EDTA and 5 mM Mal-PEG. The samples were incubated in this buffer for 10 min at
37°C. The reaction was quenched with excess DTT and centrifuged at 13,500 x g for 20
min to remove any insoluble protein. The cleared samples were then washed extensively
with buffer free of Mal-PEG using YM-30 Centricons (Millipore) to remove excess
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alkylating reagent. Thereafter, the samples were mixed with gel loading buffer and
resolved on a 6% polyacrylamide gel using electrophoresis at 30 mA current. The protein
bands were stained with coomassie blue and the band intensities were estimated with the
imaging software installed in the Gel-Doc instrument (BioRad). The midpoint potential
was calculated using equation 2, where Eo´ = -250 mV, the standard reduction potential
for DTT at pH 8 and 37°C, R is the universal gas constant, T is the temperature in
RT
[DTTred]
E = E + —— ln—————
eq. 2
nF
[DTTox]
degrees Kelvin, F is the Faraday constant, n is the number of electrons transferred and Eo
0

0’

is the redox potential under experimental conditions.

4.4 Results
Purification and redox-dependent CBS activity-The truncated dimer (CBS-ΔC143), and
full-length wild-type CBS were obtained in at least 95% purity as determined by SDSPAGE analysis and by a ratio of ~1 for the 280:428 nm absorbance (not shown). The
specific activity of the full-length enzyme and the truncated dimer in the presence of DTT
and homoserine, are 18.3 ± 1.0 and 350 ± 13 µmol•h-1•mg-1 protein compared to 350 ±40
and 600 ±70 µmol•h-1•mg-1 protein respectively in the standard assay with homocysteine.
In the absence of DTT, the activity of the truncated dimer and the full-length CBS were
4.6- and 1.6-fold lower respectively (Table 1). Glutathione (20 mM) was less effective at
reducing CBS than DTT at least under the assay conditions, and a modest 1.3 fold
increase in specific activity was observed with the truncated dimer while no effect was
detected with the full-length enzyme, probably due to the low activity associated with the
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full-length enzyme in the homoserine assay. Since the oxidized state of the heme iron in
CBS is unaffected by DTT as evidenced by the presence of a ferric Soret peak at 428 nm
(14), these results suggest that the enhancement in activity upon reduction, is due to a
change in the redox state of the cysteines.
Due to the low specific activity of full-length CBS seen in the homoserine assay,
further kinetic characterization was performed only with the truncated enzyme. The
KMHser and KMSer for the truncated dimer are 1.3 ± 0.2 mM and 1.6 ± 0.2 mM,
respectively (Table 1). These values are similar to the kinetic parameters reported earlier
for the full-length enzyme in the standard assay (KMser = 2.0 mM KMHcy = 5 mM) (7, 28).
In contrast, the KM values for serine and homocysteine reported for the truncated dimer in
the standard assay are significantly higher (KMser =18 mM and KMHcys = 9.7 mM) (7). The
basis for these differences is not known.

Table 1. Kinetic parameters for the full length and the truncated CBS using homoserine
and serine under standard assay conditions
Kma

CBS

Homoserine
Full-length

N.Dc

CBS-ΔC143

1.3 ± 0.2

a

Specific Activityb
Serine

-DTT

+DTT

Fold Activation

N.Dc

11.4 ± 0.8

18.3 ± 1.0

1.6

1.6 ± 0.2

76.4 ± 5.0

350 ±13.0

4.5

KM is in units of mM

Specific activity in units of μmoles of cystathionine formed h-1mg-1 of protein and was
determined in the presence of AdoMet for full-length CBS
b

c

Not determined
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Detection of a disulfide bond in the CBS CXXC motif by mass spectrometry-Since the
truncated variant of CBS does not exhibit the highly heterogenous oligomeric and
aggregation states seen with the full-length enzyme, MS analysis for monitoring the
redox state of the CXXC motif was conducted on this form of the enzyme. Generation of
CBS-ΔC143 leads to deletion of only one of the eleven cysteines present in the fulllength enzyme, C431, which is reported to be solvent accessible (4). Alkylation of CBSΔC143 with IAA in the presence or absence of DTT and subsequent digestion with
trypsin or Glu-C led to the identification of all nine peptides in which the ten cysteine
residues in the truncated dimer reside. The masses of the individual peptides were
determined by ESI TOF MS (Table 2) and MS/MS fragmentation pattern of each peptide
was used to confirm its identity. One peptide carried the two cysteines in the CXXC
motif. Under reducing and non-reducing conditions, the masses of all but one peptide
exhibited modification of the resident cysteine by a single IAA residue i.e., an addition of
58 Da. The exception was the peptide, KC272PGC275RIIGVDPE, which exhibited a
monoisotopic mass of 1501.69 (corresponding to the addition of two IAA residues),
under reducing conditions and a monoisotopic mass of 1383.66 (corresponding to the
presence of an intramolecular disulfide bridge) under air oxidized conditions. The +3
charge states of the two forms of the peptide are shown in Fig. 4 with m/z values of
501.57 and 462.22 for the reduced and oxidized states respectively.
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Table 2. Comparison of the expected and observed monoisotopic masses of CBS
peptide fragments with IAA–modified cysteines

Number of IAA
Molecular Weighta

Cysteine
Peptide Covering the Cysteine

Modifications

Residue
Observed

Calculated

-DTTb

+DTTc

52

CTWLGRPASESPHHHTAPAK

2368.05

2368.11

1

1

15

VGPTGCPHRSGPHSAKGSLE

2030.92

2030.96

1

1

103

FGLKCELLAK

1178.60

1178.64

1

1

109

CEFFNAGGSVK

1215.45

1215.52

1

1

346

MLIAQEGLLCGGSAGSTVAVAVK

2232.09

2232.15

1

1

370

CVVILPDSVR

1157.57

1157.61

1

1

165

CIIVMPEK

989.42

989.49

1

1

272, 275

KCPGCRIIGVDPE

1501.63

1501.69

0

2

244

ILQQCDGKLDMLVASVGTGGTITGIARKL

3272.71

3272.75

1

1

a

in Da

b

Sample was modified with IAA without reduction

c

Sample was reduced with DTT before IAA modification
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Figure 4. A. Mass analysis of the KC272PGC275RIIGVDPE peptide obtained by two
IAA modifications (under reducing conditions). The charge state is +3 and yields an Mr
of 1501.69 and an m/z value of 501.57. B. Mass analysis of the KC272PGC275RIIGVDPE
peptide containing a disulfide bridge between C272 and C275 (under air oxidized
conditions). The charge state is +3 and yields an Mr of 1383.66 and an m/z value of
462.2.

Evidence for the presence of a sulfenic acid in the CXXC motif-MS analysis of the
peptides generated under air oxidized conditions revealed a species with a +4 charge state
corresponding to an m/Z value of 365.937 as shown in Fig. 5. The monoisotopic mass of
this peptide is 1459.72 and represents the presence of a 59 Da and a 17 Da modification
corresponding to the addition of a single IAA and a hydroxyl group respectively, to
1383.66, the mass of the KC272PGC275RIIGVDPE peptide bearing a disulfide bond. The
presence of a hydroxyl group is consistent with the formation of a sulfenic acid
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modification representing an intermediate between the dithiol and disulfide states, in
which one cysteine is oxidized to sulfenic acid and the other is reduced.

Figure 5. Mass analysis of the KC272PGC275RIIGVDPE peptide bearing a sulfenic acid
derivative on one of the cysteines in the CXXC motif. The charge state is +4 and yields
an Mr of 1459.66 and an m/z value of 365.9.

Determination of the midpoint potential of the CXXC center in CBS-Although Mal-PEG 5
kD has a molecular mass of 5 kD it causes an ~20 kD shift per modified thiol in the
electrophoretic mobility of polypeptides under denaturing conditions (29). When CBSΔC143 was alkylated with Mal-PEG at varying ratios of oxidized to reduced DTT, two
bands of 245 and 205 kD molecular mass were observed (Fig. 6). The band with a
molecular mass of 245 kD represents the addition of 200 kD to the mass of CBS-ΔC143
(45 kD) and corresponds to the presence of ten Mal-PEG moieties. The lower protein
band at ~205 kD corresponds to the oxidized population of CBS bearing eight Mal-PEG
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modifications, consistent with the presence of two cysteines in a disulfide linkage. The
intensity of the higher molecular mass band decreased with a corresponding increase in
the intensity of the lower band as the ratio of reduced to oxidized DTT decreased (Fig. 6).
Quantitative analysis of the band intensities as a function of the redox potential poised by
varying ratios of oxidized to reduced DTT, yielded an estimated midpoint potential of 240 ± 4 mV for the CXXC motif in CBS.

Figure 6: Determination of the midpoint potential of the CXXC motif by alkylation
with Mal-PEG. A. Distribution of the upper and lower bands representing the reduced
and oxidized forms of CBS-ΔC143 respectively by SDS PAGE analysis. The upper band
results from two extra MAL-PEG modifications versus the population representing the
lower band. The relative intensities of the upper and lower bands depend on the ratio of
DTTred/DTTox. (B) Quantitative analysis of the data shown in A. The chart at the bottom
indicates the relative amounts of oxidized and reduced DTT in each reaction mixture. (C)
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Nernst analysis of the CXXC redox state at varying potentials poised by changing the
relative proportions of reduced and oxidized DTT.

Determination of the midpoint potential of the heme center in full-length CBSSpectroelectrochemical titrations were performed to estimate the redox potential of the
heme in full-length CBS by following the intensity of the heme Soret peak as described
under Methods. From this analysis, the average midpoint potential for the heme in wild
type full-length CBS was determined to be -356 ± 6 mV for titrations in the reductive
(average = -353 ± 6 mV) and oxidative directions (-358 ± 5 mV). Fig. 7 shows a
representative potentiometric titration of the heme in full-length CBS. The presence of
100 µM AdoMet, an allosteric activator of CBS, during the titration had no effect on the
heme redox potential.
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Figure 7. Redox potential determination for the heme in full-length CBS. The
potentiometric titration was performed at 25˚C in the presence of 20 μM benzyl viologen,
20 μM methyl viologen, 8 μM wild type CBS with 2 μM incremental addition of sodium
dithionite. The spectra are shown after mediator dye subtraction. The 428 nm ferric
species converted to the 449 nm ferrous species as sodium dithionite was added. Inset.
Nernst analysis of this data yielded a redox potential of -352 ± 4 mV for the heme with a
slope of 73 ± 7.5 mV.(Madzelan, P Banerjee R)

4.5 Discussion
CBS catalyzes the first step in the transsulfuration pathway, which converts
homocysteine to cysteine via the intermediate formation of cystathionine (Fig. 1). The
quantitative significance of this pathway for provision of intracellular cysteine, needed
for glutathione synthesis, links the metabolism of homocysteine directly to cellular redox
homeostasis (16, 17). Additionally, the activity of CBS contributes to determining the
balance between the transsulfuration and transmethylation pathways for clearing
intracellular homocysteine and thereby determining the fate of intracellular sulfur in
mammals. As expected, this critical junction in sulfur metabolism is subject to multiple
layers of regulation including regulation by AdoMet and by the ambient redox state (1).
Cell culture studies have revealed that under conditions of oxidative stress, the flux of
homocysteine through the transsulfuration pathway is increased (17). The physiological
rationale for this response is that it represents an auto corrective reaction that, by
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increasing synthesis of cysteine stimulates synthesis of glutathione, thereby replenishing
the antioxidant pool, which is depleted under oxidizing conditions. The mechanism of upregulation of the transsulfuration flux is however, not known. Studies with purified
recombinant human CBS have revealed that the enzyme is approximately two-fold less
active when low potential reductants viz. titanium citrate or dithionite are added to the
standard assay mixture (14). Furthermore, this change in activity is correlated with a
change in the redox state of the heme from the ferric to the ferrous state (14) and is
unaffected by mutation of either cysteine in the CXXC motif (15). These observations
support our earlier conclusion that under the conditions of the in vitro assay, the heme
rather than the CXXC motif in CBS, is the redox sensor (15). However, the role of the
CXXC motif in redox regulation of CBS cannot be assessed in this assay for the
following reason. One of the substrates of CBS, homocysteine, is itself a thiol and, at the
high concentrations that it is present in the standard reaction mixture (30 mM), would
reduce the CXXC disulfide. Hence, under the standard assay conditions, the CXXC motif
is in the reduced state, and only redox regulation by the heme can be interrogated.
Mutation of the cysteines in the CXXC motif mimics the reduced dithiol state of this
motif, and the resulting mutants are expected to retain heme-dependent redox sensitivity,
as reported (15). Hence, the influence of the CXXC redox state on the activity of CBS
has not been previously addressed and, in the absence of the values for the midpoint
potentials for the two redox centers in CBS, their physiological relevance to redox
responsiveness, has not been evaluated.
To address these gaps in our understanding of the redox regulation of CBS, we have
developed a new assay for the enzyme that uses the hydroxo-derivative of homocysteine,
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homoserine (Fig. 3). Despite the significant difference in the pKa of the thiol group in
homocysteine (~10.8) versus homoserine (~15), only a 19-fold lower activity is seen with
the full-length enzyme when homoserine replaces homocysteine in the assay (18.3 ± 1.0
versus 350 ± 40 µmol•h-1•mg protein-1). This suggests that deprotonation of
homocysteine for the β-replacement reaction, is not completely rate limiting. With the
truncated dimeric CBS, an even smaller 1.7-fold difference is observed between the two
substrates (350 ± 13 versus 600 ±70 µmol•h-1•mg protein-1). Both forms of the enzyme
however exhibit higher activity in the homoserine assay in the presence of DTT,
indicating that the dithiol form of the CXXC motif in CBS is associated with more active
enzyme.
MS analysis was employed to verify the difference in the oxidation state of the
CXXC motif suggested by the difference in the enzyme activity assays in the presence
and absence of DTT. A combination of trypsin and Glu-C resulted in the recovery of all
nine peptides harboring the ten cysteine residues in the truncated form of CBS, and
confirmed the presence of a disulfide bond in the CXXC motif in the protein as isolated
and its reduction in DTT-treated samples (Table 2 and Fig. 4).
Reversible cysteine-targeted oxidative modifications such as formation of
intramolecular disulfides, is a common strategy for regulating proteins under oxidative
stress conditions (30). An example of a PLP-dependent enzyme that is subject to such
regulation is human mitochondrial branched chain aminotransferase (31). The latter, like
CBS, contains a regulatory CXXC motif involving cysteines 315 and 318. In the C318A
mutant of the branched chain aminotransferase, C315 was shown to form a sulfenic acid
intermediate, suggesting that this is the reactive cysteine that is initially oxidized during
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formation of the disulfide bond. We also detected a sulfenic acid intermediate in CBS by
mass spectrometry (Fig. 5). In the protein as isolated, this species is present at low
abundance as suggested by the relatively low intensity associated with this signal, which
precluded assignment by MS/MS analysis of the particular cysteine in the CXXC motif
that is oxidized to sulfenic acid. The instability of the previously reported C272A or
C275A mutants of CBS (15) has similarly limited efforts to identify the reactive (versus
resolving) cysteine in the CXXC motif.
Disulfide bonds have traditionally been considered to be either catalytic or structural
in function. There is however growing recognition of a third class of disulfides, the
allosteric disulfide bonds, which are capable of controlling protein function by triggering
a conformational change. A recent analysis of protein crystal structures has revealed
differences in disulfide bond geometry and in disulfide strain energy between structural,
catalytic and allosteric disulfide bonds (32). Disulfides with low dihedral strain energies,
typically between 9.7-10.4 kJ mol-1 are assigned to be structural in nature whereas those
with higher values are assigned as either catalytic or allosteric in function (≥ 12 kJ mol-1),
with the catalytic disulfides typically having higher values than the allosteric ones (32).
Based on this analysis, the C272-C275 disulfide bond in CBS is classified as a /+RHHook catalytic bond of the type seen in oxidoreductases (e.g. thioredoxin) and
isomerases (e.g. protein disulfide isomerase) rather than an allosteric disulfide bond,
which have the –RHStaple configuration (32). The estimated dihedral strain energy of the
disulfide bond in the structure of truncated CBS (PDB 1JBQ) is 15.95 kJ mol-1, which
also places it in the category of catalytic disulfides. However, given the distance between
the C272-C275 bond and the active site (Fig. 2), it appears unlikely that these residues
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play a catalytic role, nor is this warranted based on the PLP-dependent β-replacement
chemistry of the reaction. In addition, mutation of the cysteines in the CXXC motif
results in retention of enzyme activity (15), excluding an essential role for these residues
in catalysis. It is possible however that the CXXC motif in CBS may be involved in
interactions with and/or regulation of other proteins. It is important to note however that
while the CXXC motif appears to be relatively surface exposed in the structures of the
truncated CBS dimer (15, 19), its accessibility in the full-length protein is not known.
The CXXC motif in CBS sequences is generally correlated with the presence of the
putative heme ligands and suggests that they may both function in a regulatory capacity
(1). In fact, the eleven cysteine residues found in human CBS are highly conserved across
other mammalian CBSs. In the native full-length human protein, only two cysteines are
reported to be readily solvent accessible, C15 in the heme domain and C431 in the
regulatory domain (4). However, the highly heterogeneous oligomeric state of purified
recombinant human CBS, even in the presence of DTT, substrates or AdoMet
(unpublished observations), limits such analysis.
The opposing effects of the oxidation states of the two redox centers on the activity of
CBS, i.e. activation by reduction of the disulfide and oxidation of the heme, seems at first
glance, to be paradoxical. However, inspection of the predicted dependence of CBS
activity on the ambient redox potential (Fig 8), reveals that the presence of these two
centers can fine-tune its responsiveness to redox changes. The cytoplasmic redox
potential is poised by the glutathione, NADPH, dihydrolipoamide and thioredoxin redox
couples. In mammalian cells, this value has been estimated to be ~-315 to -325 mV (33).
The thiol/disulfide redox couple in CBS has a midpoint potential of -240 mV and under
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physiological conditions the CXXC motif is likely to be predominantly reduced. In
contrast, the heme has a lower midpoint potential of -356 mV, which is similar to values
reported for other heme-thiolate proteins such as cytochrome P450 (-360 mV) (34), nitric
oxide synthase (-347 mV) (35), and CooA (-320 mV) (36). We note that we have also
determined the redox potential of the heme in the truncated dimeric form of CBS and
found it to be -287 ± 2 mV (37). The difference in redox potential from the value
measured for the full-length enzyme in this study, likely derives from changes in the
heme microenvironment and/or heme solvent exposure between the two enzyme forms.
The heme in full-length CBS is expected to exist as a mixture of the ferric and ferrous
states under physiological conditions. Under oxidative stress conditions, an increase in
the proportion of the oxidized heme would be primarily responsible for an increase in
CBS activity (Fig. 8).

Figure 8. Schematic representation of the relative change in CBS activity with redox
potential.
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We note however, that varying estimates for the ambient cytoplasmic redox potential
have been reported in the literature. Based on the ratio of reduced to oxidized glutathione,
values ranging from -200 to -240 mV have been reported (38, 39). A similar value for the
intracellular potential in E. coli (-259 mV) has been reported using a green fluorescent
protein-based sensor responsive to the glutathione/glutathione disulfide redox couple
(40). These higher values predict a different distribution of the oxidized and reduced
forms of the heme and CXXC centers under normoxic conditions and activation of CBS
would be expected under conditions that shift the redox potential to be more reducing
rather than oxidizing (Fig. 8), which is not observed in mammalian cells (17).
Another example of a protein whose activity is modulated both by the oxidation state
of its heme and by an intramolecular disulfide/dithol equilibrium is neuroglobin (41). The
heme in neuroglobin is hexacoordinate with bis-histidine axial ligands. Binding of
oxygen to the heme therefore depends on the histidine dissociation rate as well as the
relative association rates of oxygen and the competing distal histidine ligand. Reduction
of the disulfide bond in neuroglobin results in a significant decrease in oxygen affinity,
which in turn results from a decrease in the dissociation rate of the histidine. It is not
known to what extent the redox state of the CXXC motif in CBS influences the reactivity
of the heme to exogenous ligands.
The thiol versus disulfide state of a protein can have other functional consequences.
For instance, the nuclear localization of the redox sensitive YAP1 transcription factor is
triggered by reduction of a regulatory disulfide, which exposes the nuclear localization
signal (42). We have recently reported that CBS is a target of sumoylation and that it
localizes to the nucleus in addition to its well known cytoplasmic residence (43). The role
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of CBS inside the nucleus or the mechanism of its import into this compartment is not
known. It is also not known whether the redox state of the CXXC motif has any influence
on the nuclear function and/or localization of CBS.
In summary, we report that in addition to the oxidation state of the heme, the redox
state of the CXXC motif potentially serves as another switch for fine-tuning the redox
responsiveness of the enzyme. The midpoint potentials of the heme and CXXC centers in
human CBS reported in this study allows prediction of how the activity of this enzyme
may be modulated by changes in the ambient intracellular redox potential.
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Chapter 5
Summary and future directions
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Summary
CBS is the first enzyme in the transsulfuration pathway which commits homocysteine
to cysteine synthesis and is subject to complex regulation. Although it was known that
CBS undergoes intrasteric and allosteric regulation, insights into the structural basis of
this regulation were obtained for the first time in this study. In addition, this thesis
elucidated the role of the CXXC motif and established its redox-dependent role in
regulating CBS.
The first part of this dissertation sheds light on localizing conformational changes
associated with allosteric and intrasteric regulation of human CBS. CBS functions at a
critical metabolic junction where the decision to conserve homocysteine via the
methionine cycle or to commit it to transsulfuration and therefore cysteine synthesis is
made. It is thus expected that the enzyme is tightly regulated. This includes intrasteric
inhibition imposed by the C-terminal domain and allosteric regulation by AdoMet.
Interestingly, a subset of pathogenic CBS mutations have been reported that map to the
regulatory domain, display a higher level of basal activity but are nonresponsive to
allosteric activation. The structural basis for this apparently paradoxical phenotype has
been investigated for the first time in this study.
Kinetic studies indicate that the wild-type enzyme equilibrates between at least two
conformations, the “basal” state and the “activated state” that is induced by AdoMet. We
employed H/D exchange MS to localize focal conformational changes in wild-type CBS
induced by AdoMet, to a peptide which spans residues 511-531 in the regulatory domain.
We surmise that this region becomes more exposed to solvent in the presence of AdoMet.
Interestingly this “activated” conformation is mimicked by the pathogenic mutation
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D444N, which has a kcat similar to that of the “activated” state of the wild-type enzyme
but is nonresponsive to AdoMet. Interestingly the 511-531 peptide is located in the Cterminal module of the enzyme where AdoMet is predicted to bind. This domain
comprises a tandem repeat of two CBS domains. Since the structure of the full-length
CBS is unavailable, we have generated a homology modeled structure of the C-terminal
regulatory domain using the coordinates for a CBS domain protein from
M.thermoautotrophicus. The sensitivity of the 511-531 peptide could be consequential of
its proximity to the binding site for AdoMet and/or its location on the pathway of
allosteric signal transduction.
The kinetics of hydrogen exchange further revealed two surfaces represented by
peptides 356-370 and 371-385, which are sensitive to deletion of the regulatory domain.
Interestingly several pathogenic mutations including R369C/H and K384N/E have been
reported in these two stretches. We have employed the H/D exchange MS data in
conjunction with the reported properties of CBS guide our docking model for the fulllength enzyme. We reasoned, based on biochemical data that the 356-370 peptide is
involved in making direct contact with the regulatory domain and hence maps on to the
regulatory-catalytic interface. The 371-385 peptide on the other hand is located at the
bottom of a cavity and leads to a short helix leading to a loop representing the C-terminus
of the catalytic domain. We employed the docked model of the full-length dimeric CBS
to generate a model of the full-length tetramer. in the absence of a full-length crystal
structure, this model has been used to rationalize the pathological basis of several patient
mutants.
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The second part of this dissertation describes the characterization of the linked
P78R/K102N pathogenic mutation in the catalytic core of CBS. The mutants P78R and
K102N were created to study the contributions of each locus to the linked mutant. The
P78R mutant which existed as a mixture of a full-length dimeric form and higher order
oligomers, allowed for the first time limited kinetic characterization of the full-length
dimeric state of CBS. Upon activation at 4°C, the higher order oligomers converted to the
apparently more stable full-length dimer exhibiting a different specific activity. These
results suggest the possibility that CBS may distribute itself into various oligomeric states
under specific cellular conditions and/or in different compartments and that this may
represent yet another mode of regulation.
The unresponsiveness of the P78R/K102N mutant towards AdoMet makes it the first
catalytic core mutation reported with such a phenotype. H/D exchange studies conformed
that the double mutant exhibited a similar conformation as seen in the D444N mutant
indicating that it is also locked in kinetically “activated” state. The finding of AdoMet
nonresponsive mutants in both the catalytic as well as the regulatory domains is
consistent with the interactions between the two domains.
The third and the final portion of this thesis focused on redox regulation of CBS. For
the first time it was established that the CXXC motif in CBS is redox active. The change
in the redox state of the CXXC motif is communicated to the catalytic center which
causes an increase in activity (4.5-fold in the truncated dimer and 1.6-fold in the fulllength enzyme), upon reduction of the disulfide to a dithiol. This modulation in the
activity with respect to the redox changes at the CXXC center is opposite to that seen at
the heme center where a reduction of the iron actually decreased the activity by ~2 fold.
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The reciprocal redox dependency associated with the two centers would represent a
mechanism for fine tuning the global redox regulation of CBS. The midpoint potentials of
the heme (-356 ± 6mV) and the CXXC center (-240 ± 4mV) reported in this study allows
prediction of how CBS activity may be modulated by changes in the ambient redox
potential.

Future directions
The physiological relevance of the existence of CBS in various oligomeric forms is
yet to be established. Characterization of various mutants have revealed the existence of a
mixture of higher order oligomers (including tetramers) and full-length dimers such as
seen in the P78R mutant as detected in this thesis. It would be interesting to study the
oligomeric distribution of CBS in vivo, to assess whether the sampling of different
oligomeric states is seen and if it changes under different conditions i.e. oxidative stress
or methionine restriction. Investigations to detect the oligomeric state of CBS in the
different cellular compartments where it localizes (i.e. in nucleus and the cytoplasm),
may further shed light on its diverse functioning.
An important area that can also be further developed, is redox regulation of CBS. In
vitro studies have identified the redox regulatory centers in CBS. As a next step, the
redox status of the enzyme will have to be established in vivo. It would be interesting to
study the redox status of this enzyme both in the cytoplasm and nucleus. Investigations
should be concluded to assess if localization of CBS and/or its function in the nucleus is
redox dependent.
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Although a change in the redox state in the CXXC motif in CBS has been shown to
be communicated to the active site, the mechanism of this transmission is yet to be
investigated. Studies aimed at mapping conformational changes if any, or interaction with
potential redox partners via the CXXC center will address important gaps in our
knowledge of redox regulation of CBS in vivo.

